<SEC-DOCUMENT>0001493152-22-030374.txt : 20221103
<SEC-HEADER>0001493152-22-030374.hdr.sgml : 20221103
<ACCEPTANCE-DATETIME>20221103172056
ACCESSION NUMBER:		0001493152-22-030374
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20221103
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221103
DATE AS OF CHANGE:		20221103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		221359179

	BUSINESS ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		646-813-4701

	MAIL ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:ABEO="http://abeonatherapeutics.com/20221103">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_ABEO_abeonatherapeutics.com_20221103 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20221103_20221103 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000318306 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-11-03to2022-11-03" name="dei:EntityCentralIndexKey">0000318306</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-11-03to2022-11-03" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abeo-20221103.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-11-03to2022-11-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-03</xbrli:startDate>
        <xbrli:endDate>2022-11-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90E_edei--DocumentType_c20221103__20221103_z5aWhvVWWXDg"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PURSUANT
TO SECTION 13 OR 15(D) OF THE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of report (Date of earliest event reported): <span id="xdx_906_edei--DocumentPeriodEndDate_c20221103__20221103_zVLjuk2skKE8"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">November 3, 2022</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_900_edei--EntityRegistrantName_c20221103__20221103_zqr9cj4Ic5ib"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" name="dei:EntityRegistrantName">ABEONA THERAPEUTICS INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20221103__20221103_zTQrxNuPadB4"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityFileNumber_c20221103__20221103_z5zRDdDhvDW2"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" name="dei:EntityFileNumber">001-15771</ix:nonNumeric></span></span></b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20221103__20221103_zHFYp0qhSQH2"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" name="dei:EntityTaxIdentificationNumber">83-0221517</ix:nonNumeric></span></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of<br />
    incorporation)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    <br />
    File Number)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer <br />
    Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressAddressLine1_c20221103__20221103_zrWiydFv97u3"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" name="dei:EntityAddressAddressLine1">1330
Avenue of the Americas</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressAddressLine2_c20221103__20221103_zLavOKUmaDk1"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" name="dei:EntityAddressAddressLine2">33rd Floor</ix:nonNumeric></span>, </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20221103__20221103_zQYq9SX93dCe"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" name="dei:EntityAddressCityOrTown">New
York</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20221103__20221103_z3qUQEwHNJz2"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressPostalZipCode_c20221103__20221103_zGSyR1XHBwq6"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" name="dei:EntityAddressPostalZipCode">10019</ix:nonNumeric> </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>(Address
of principal executive offices) (Zip Code)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_908_edei--CityAreaCode_c20221103__20221103_z5wumeLGF904"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" name="dei:CityAreaCode">(646)</ix:nonNumeric>
</span><span id="xdx_90E_edei--LocalPhoneNumber_c20221103__20221103_z2XZgL7tTeHe"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" name="dei:LocalPhoneNumber">813-4712</ix:nonNumeric></span></span></b><br />
(Registrant&#8217;s telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">N/A</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--WrittenCommunications_c20221103__20221103_zzdpPVk1R2x6"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_edei--SolicitingMaterial_c20221103__20221103_zgmQSGNIfyxi"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--PreCommencementTenderOffer_c20221103__20221103_zNcXaVCluiz8"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20221103__20221103_z6FDZ5Cqucm4"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--Security12bTitle_c20221103__20221103_z2im2ZGUOUfd"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" name="dei:Security12bTitle">Common
    Stock, $0.01 par value</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--TradingSymbol_c20221103__20221103_zH2kLEOVL676"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" name="dei:TradingSymbol">ABEO</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_905_edei--SecurityExchangeName_c20221103__20221103_z9ZbAng7kNPb"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_902_edei--EntityEmergingGrowthCompany_c20221103__20221103_zvy9DYpZONSd"><ix:nonNumeric contextRef="From2022-11-03to2022-11-03" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1.01</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry
    into a Material Definitive Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2022, Abeona Therapeutics Inc. (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement (the &#8220;Purchase
Agreement&#8221;) with a group of investors (the &#8220;Purchasers&#8221;) providing for the private placement (the &#8220;Private Placement&#8221;)
to the Purchasers of (i) 7,065,946 shares of the Company&#8217;s common stock, par value $0.01 per share (the &#8220;Common Stock&#8221;)
(ii) pre-funded warrants to purchase 543,933 shares of Common Stock with a term of five years from the issuance date (the &#8220;Pre-Funded
Warrants&#8221;) and (iii) warrants to purchase 7,609,879 shares of Common Stock with a term of five years from the issuance date (the
&#8220;Common Warrants&#8221; and together with the Pre-Funded Warrants, the &#8220;Warrants&#8221;), for an aggregate purchase price
of approximately $35.0 million. Each Pre-Funded Warrant has an exercise price of $0.01 per share of Common Stock. Each of the Warrants
is subject to customary adjustments. The closing of the Private Placement is expected to occur on November 7, 2022 (the &#8220;Closing&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Common Warrant has an exercise price of $4.75 per share. The Warrants may not be exercised if the aggregate number of shares of the Common
Stock beneficially owned by the holder thereof would exceed 4.99% immediately after exercise thereof, which ownership cap may be increased
by the holder up to 9.99% upon 61 days&#8217; prior notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds from the Private Placement for development, working capital and general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities issued to the Purchasers under the Purchase Agreement were offered in reliance on an exemption from registration provided
by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder. The Company relied on this exemption from
registration based in part on representations made by the Purchasers, including that each of the Purchasers is an &#8220;accredited investor&#8221;,
as defined in Rule 501(a) promulgated under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cantor
Fitzgerald &amp; Co. served as the placement agent in connection with the Private Placement, and the Company has agreed to pay Cantor
Fitzgerald &amp; Co. a customary fee plus reimbursement for certain out-of-pocket expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sale of the securities pursuant to the Purchase Agreement has not been registered under the Securities Act or any state securities laws.
The securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Neither this Current Report on Form 8-K, nor the exhibits attached hereto, is an offer to sell or the solicitation of an offer to buy
the securities described herein or therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Purchasers will enter into a Registration Rights Agreement immediately prior to the Closing, pursuant to which the Company
will agree to prepare and file a registration statement with the Securities and Exchange Commission no later than the 30<sup>th</sup>
day following the execution of the Registration Rights Agreement to register the resale of the shares of Common Stock and the shares
of Common Stock issuable upon exercise of the Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
foregoing description of the Purchase Agreement, the Pre-Funded Warrants, the Common Warrants and the Registration Rights Agreement is
only a summary and is qualified in its entirety by reference to the full text of such documents, which are filed as Exhibits 10.1, 4.1,
4.2 and 4.3, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    3.02</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Unregistered
    Sales of Equity Securities.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
information contained in Item 1.01 of this Current Report on Form 8-K with respect to the issuance of the securities in the Private Placement
is incorporated by reference under this Item 3.02.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    8.01</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
    Events.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
November 3, 2022, the Company issued a press release announcing the Private Placement. A copy of such press release is filed as Exhibit
99.1 to this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9.01</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)
Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Form of Warrant</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-2.htm">Form of Pre-Funded Warrant</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-3.htm">Form of Registration Rights Agreement</a></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Securities Purchase Agreement dated November 3, 2022</a></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press Release dated November 3, 2022</a></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURE
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
    Therapeutics Inc.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Joseph Vazzano</i></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Vazzano</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
November 3, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2WlK3nwsvk4rIIiSi2y3HWNIdmd3+Hqm3bFWiYWAYzvnOESIUK1rqGhlO8yKHAzZtrRxCgRUymgt6R7bepOBvgVdtHSvj+vcHZuQZ9Mx0lMzOXuitD22xTCFJongcSQmxTOUE9lsRdHpGptIlGqdVDcqUsGdqWaNT/B4SDupFhpp3X3VEtpqMjxvFg/wBGScSdvRQT+KbhTzPRBD2E4gV073tau7WUQOLGhvfZQf0v8EXFbVJRQ== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMON
STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Abeona
Therapeutics Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
Shares: _______</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
                                            Date: November <U>__</U>, 2022</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, [&#9679;] or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on [&#9679;]<SUP>1
</SUP>(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Abeona Therapeutics Inc., a
Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to <U>_____ </U>shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant
Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated November 3, 2022, among the Company and the purchasers
signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy
or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of
Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United
States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.
No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has
been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading
Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard
Settlement Period (as defined in Section 2(d)(i) herein) following the date of receipt of such notice. <B>The Holder and any assignee,
by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a
portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less
than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP><U>NTD</U>: Expiration date will be 5 years after the issue date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&nbsp;<U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$____</B> subject to adjustment hereunder (the
&ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&nbsp;<U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in
part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.2in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD><TD STYLE="text-align: center; width: 0.25in">=</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
is executed and delivered during &ldquo;regular trading hours&rdquo; on a Trading Day pursuant to Section 2(a) hereof (2) both executed
and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (3) both executed and delivered pursuant to Section
2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS
promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading
Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading
Market as reported by Bloomberg L.P. (&ldquo;Bloomberg&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable Notice
of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within
two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant
to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a
Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular
trading hours&rdquo; on such Trading Day;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99pt; text-align: left; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.2in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD><TD STYLE="text-align: center; width: 0.25in">=</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> the Exercise
Price of this Warrant, as adjusted hereunder; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.2in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)</FONT></TD><TD STYLE="text-align: center; width: 0.25in">=</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of
Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: left; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant
Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this
Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Mechanics
                                            of Exercise</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.&nbsp;<U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust
Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such
system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the
Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations
pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in
the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is
entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the later of
(i) the earlier of (a) two (2) Trading Days after the delivery to the Company of the Notice of Exercise and (b) the number of Trading
Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise, and (ii) one (1) Trading
Day after delivery of the aggregate Exercise Price to the Company (provided the foregoing clause (ii) shall not apply in the event of
a cashless exercise) (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the
Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this
Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number
of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. As used herein, &ldquo;<U>Standard
Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary
Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.&nbsp;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: left; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.&nbsp;<U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.&nbsp;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Holder&rsquo;s
                                            Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and
                                            a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section
                                            2 or otherwise, to the extent that after giving effect to such issuance after exercise as
                                            set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s
                                            Affiliates and any other Person whose beneficial ownership of Common Stock would be aggregated
                                            with the Holder&rsquo;s for purposes of Section 13(d) or Section 16 of the Exchange Act and
                                            the applicable regulations of the SEC, including any &ldquo;group&rdquo; of which such Holder
                                            is a member (together, the &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially
                                            own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of
                                            the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder
                                            and its Attribution Parties shall include the number of shares of Common Stock issuable upon
                                            exercise of this Warrant with respect to which such determination is being made, but shall
                                            exclude the number of shares of Common Stock which would be issuable upon (i) exercise of
                                            the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any
                                            of its Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted
                                            portion of any other securities of the Company (including, without limitation, any other
                                            Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to
                                            the limitation contained herein beneficially owned by the Holder or any of its Attribution
                                            Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e),
                                            beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange
                                            Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder
                                            that the Company is not representing to the Holder that such calculation is in compliance
                                            with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules
                                            required to be filed in accordance therewith. To the extent that the limitation contained
                                            in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in
                                            relation to other securities owned by the Holder together with any Attribution Parties) and
                                            of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder,
                                            and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
                                            of whether this Warrant is exercisable (in relation to other securities owned by the Holder
                                            together with any Attribution Parties) and of which portion of this Warrant is exercisable,
                                            in each case subject to the Beneficial Ownership Limitation. To ensure compliance with this
                                            restriction, the Holder will be deemed to represent to the Company each time it delivers
                                            a Notice of Exercise that such Notice of Exercise has not violated the restrictions set forth
                                            in this paragraph and the Company shall have no obligation to verify or confirm the accuracy
                                            of such determination. In addition, a determination as to any group status as contemplated
                                            above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules
                                            and regulations promulgated thereunder. For purposes of this Section 2(e), in determining
                                            the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
                                            shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual
                                            report filed with the Commission, as the case may be, (B) a more recent public announcement
                                            by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting
                                            forth the number of shares of Common Stock outstanding. Upon the written or oral request
                                            of a Holder, the Company shall within one Trading Day confirm orally and in writing to the
                                            Holder the number of shares of Common Stock then outstanding. In any case, the number of
                                            outstanding shares of Common Stock shall be determined after giving effect to the conversion
                                            or exercise of securities of the Company, including this Warrant, by the Holder or its Attribution
                                            Parties since the date as of which such number of outstanding shares of Common Stock was
                                            reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall initially be 4.99%
                                            or, at the election of the Holder given prior to the issuance of this Warrant, 9.99% of the
                                            number of shares of the Common Stock outstanding immediately after giving effect to the issuance
                                            of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice
                                            to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of
                                            this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds
                                            19.99% of the number of shares of the Common Stock outstanding immediately after giving effect
                                            to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder
                                            and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial
                                            Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice
                                            is delivered to the Company. The provisions of this paragraph shall be construed and implemented
                                            in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct
                                            this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
                                            Beneficial Ownership Limitation herein contained or to make changes or supplements necessary
                                            or desirable to properly give effect to such limitation. The limitations contained in this
                                            paragraph shall apply to a successor holder of this Warrant.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)&nbsp;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&nbsp;<U>Pro
Rata Distributions.</U> During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) other than dividends or distributions subject to Section
3(a) (a &ldquo;<B>Distribution</B>&rdquo;), other than a reclassification as to which Section 3(c) applies, then in each such case, at
any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<I>provided</I>,
<I>however</I>, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person (excluding a merger effected solely to change the Company&rsquo;s
name), (ii) the Company (and all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment,
transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii)
any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant
to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has
been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more
related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange
pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company,
directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or
group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any
shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons
making or party to, such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary,
in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option,
exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the
date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder
an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date
of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental Transaction is not within the Company&rsquo;s
control, including not approved by the Company&rsquo;s Board of Directors, Holder shall only be entitled to receive from the Company
or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised
portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental
Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock
are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided,
further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such
holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following
such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant
based on the Black Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of
consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding
to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction
and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function
on Bloomberg (determined utilizing a 365-day annualization factor) as of the Trading Day immediately following the public announcement
of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the
sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such
Fundamental Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the announcement
of the applicable Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the
Trading Day of the Holder&rsquo;s request pursuant to this Section 3(d) and (D) a remaining option time equal to the time between the
date of the public announcement of the applicable Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The
payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within
the later of (i) five (5) Trading Days of the Holder&rsquo;s election and (ii) the date of consummation of the Fundamental Transaction.
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of
this section 3(b) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder
(without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange
for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to
this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity)
equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on
the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder
to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the
purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and
which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor
Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this
Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power of
the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity
had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)&nbsp;<U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)&nbsp;<U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of
Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights)
are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent,
together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent
or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required,
such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full,
in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers
an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&nbsp;<U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical
with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&nbsp;<U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)&nbsp;<U>Transfer
Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this
Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable
state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information
requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of
this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)&nbsp;<U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)&nbsp;<U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to
Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required
to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&nbsp;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)&nbsp;<U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)&nbsp;<U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)&nbsp;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)&nbsp;<U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of
this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which
results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs
and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the
Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)&nbsp;<U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)&nbsp;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)&nbsp;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)&nbsp;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)&nbsp;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)&nbsp;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Common Stock Purchase Warrant to be executed by its officer thereunto duly authorized as
of the date first above indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ABEONA
                                            THERAPEUTICS INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:
ABEONA THERAPEUTICS INC. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&nbsp;The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)&nbsp;Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)&nbsp;Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
                                            Print)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature: _______________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:_______________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ex4-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRE-FUNDED
COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Abeona
Therapeutics Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant</FONT> Shares:</TD>
    <TD>___________________&nbsp;</TD>
  <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue Date: November___ , 2022</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, [&#9679;] or its assigns
(the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) until this Warrant is exercised in
full (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Abeona Therapeutics Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), up to <U>_____ </U>shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant
Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated November 3, 2022, among the Company and the
purchasers signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile
copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the
&ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days
comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the
Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire
transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c)
below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any
medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has
purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of
Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of
Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder
in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of
Exercise within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period (as defined in Section 2(d)(i) herein) following the date of receipt of such notice. <B>The Holder and any assignee, by
acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a
portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less
than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Exercise
Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.01 per Warrant Share, was
pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the
nominal exercise price of $0.01 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise
of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate
exercise price under any circumstance or for any reason whatsoever. The remaining unpaid exercise price per share of Common Stock
under this Warrant shall be $0.01, subject to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Cashless
Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in
which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by
(A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.2in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD><TD STYLE="text-align: center; width: 0.25in">=</TD><TD STYLE="text-align: justify">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1) is executed and delivered during &ldquo;regular trading hours&rdquo; on a Trading Day pursuant to Section 2(a) hereof
(2) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (3) both executed and delivered
pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b)
of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the
VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock
on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;Bloomberg&rdquo;) as of the time of the Holder&rsquo;s execution
of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day
and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo;
on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such
Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after
the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.2in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD><TD STYLE="text-align: center; width: 0.25in">=</TD><TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.2in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)</FONT></TD><TD STYLE="text-align: center; width: 0.25in">=</TD><TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant
Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this
Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Mechanics of Exercise</U>.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the
Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The
Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a
participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares
to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or
manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of
a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant
Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by
the date that is the later of (i) the earlier of (a) two (2) Trading Days after the delivery to the Company of the Notice of
Exercise and (b) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the
Notice of Exercise, and (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company (provided the
foregoing clause (ii) shall not apply in the event of a cashless exercise) (such date, the &ldquo;<U>Warrant Share Delivery
Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the
holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery
of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is
received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period following delivery of the Notice of Exercise. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the
standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the
Common Stock as in effect on the date of delivery of the Notice of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of
this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of
this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates and any other Person whose beneficial ownership of Common Stock would be aggregated with the Holder&rsquo;s for purposes of Section 13(d) or Section 16 of the Exchange Act and the applicable regulations of the SEC, including any &ldquo;group&rdquo; of which such Holder is a member (together, the &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation. To ensure compliance with this restriction, the Holder will be deemed to represent to the Company each time it delivers a Notice of Exercise that such Notice of Exercise has not violated the restrictions set forth in this paragraph and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in
shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock
outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately
adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section
3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such
dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person (excluding a merger effected solely to
change the Company&rsquo;s name), (ii) the Company (and all of its Subsidiaries, taken as a whole), directly or indirectly, effects
any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or
a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the
Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their
shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock,
(iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or
recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a
reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such
other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock
held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to,
such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then,
upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder
(without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the
successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the
&ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of
shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to
any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the
Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of
the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any
exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the
obligations of the Company under this Warrant in accordance with the provisions of this section 3(b) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such
Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the
Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of
Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this
Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares
of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction
and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose
of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which
is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the
Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the
provisions of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise
every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect
as if such Successor Entity had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case
may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions
of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration
rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its
designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the
Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such
surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall
issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be
cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the
Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this
Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of
Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the
Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the
Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be
divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue
Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat
the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the
Holder, and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the
transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act
and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or
current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer,
that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any
exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for
distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state
securities law, except pursuant to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as
expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless
exercise&rdquo; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no
event shall the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the
Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if
mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in
lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding
Trading Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
Authorized Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be
determined in accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the
Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities
laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other
provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of
this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be
sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of
appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its
rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be
delivered in accordance with the notice provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to
purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the
Company or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be
entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not
to assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
and shall be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the
Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the
remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a
part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ABEONA
    THERAPEUTICS INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:
ABEONA THERAPEUTICS INC. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if
any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:<U>____________________</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
Address:<U>_____________________</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>ex4-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
RIGHTS AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Registration Rights Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is made and entered into as of November [___], 2022, between Abeona
Therapeutics Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each of the purchasers signatory hereto (each such
purchaser, a &ldquo;<U>Purchaser</U>&rdquo; and, collectively, the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser
(the &ldquo;<U>Purchase Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and each Purchaser hereby agrees as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Definitions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capitalized
terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the
Purchase Agreement.</B> As used in this Agreement, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Advice</U>&rdquo;
shall have the meaning set forth in Section 6(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Change
of Control</U>&rdquo; means an event or series of events (i) as a result of which any &ldquo;person&rdquo; or &ldquo;group&rdquo; (as
such terms are used in Sections 13(d) and 14(d) of the Securities Act) becomes the &ldquo;beneficial owner&rdquo; (as defined in Rules
13d-3 and 13d-5 under the Exchange Act, except that a person or group shall be deemed to have &ldquo;beneficial ownership&rdquo; of all
Common Stock that such person or group has the right to acquire, whether such right is exercisable immediately or only after the passage
of time (such right, an &ldquo;option right&rdquo;)), directly or indirectly, of fifty percent (50%) or more of the Common Stock entitled
to vote for members of the Company&rsquo;s Board of Directors on a fully diluted basis (and taking into account all such Common Stock
that such person or group has the right to acquire pursuant to any option right); or (ii) that results in the sale of all or substantially
all of the assets or businesses of the Company and its consolidated subsidiaries, taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the U.S. Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Violations</U>&rdquo; shall have the meaning set forth in Section 5(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effectiveness
Date</U>&rdquo; means, with respect to the Initial Registration Statement required to be filed hereunder, the 30<SUP>th</SUP> calendar
day following the filing thereof (or, in the event of a &ldquo;limited review&rdquo; by the Commission, the 60<SUP>th</SUP> calendar
day following the filing thereof, and in the event of a &ldquo;full review&rdquo; by the Commission, the 90<SUP>th</SUP> calendar day
following the filing thereof) and with respect to any additional Registration Statements which may be required pursuant to Section 2(e)
or Section 3(c), the 30<SUP>th</SUP> calendar day following the date on which an additional Registration Statement is required to be
filed hereunder (or, in the event of a &ldquo;limited review&rdquo; by the Commission, the 60<SUP>th</SUP> calendar day following the
filing thereof, and in the event of a &ldquo;full review&rdquo; by the Commission, the 90<SUP>th</SUP> calendar day following the date
such additional Registration Statement is required to be filed hereunder); <U>provided</U>, <U>however</U>, that in the event the Company
is notified by the Commission that one or more of the above Registration Statements will not be reviewed or is no longer subject to further
review and comments, the Effectiveness Date as to such Registration Statement shall be the fifth Trading Day following the date on which
the Company is so notified if such date precedes the dates otherwise required above, provided, further, if such Effectiveness Date falls
on a day that is not a Trading Day, then the Effectiveness Date shall be the next succeeding Trading Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effectiveness
Period</U>&rdquo; shall have the meaning set forth in Section 2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Event</U>&rdquo;
shall have the meaning set forth in Section 2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Event
Date</U>&rdquo; shall have the meaning set forth in Section 2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Filing
Date</U>&rdquo; means, with respect to the Initial Registration Statement required hereunder, the 30<SUP>th</SUP> calendar day following
the date hereof, and, with respect to any additional Registration Statements which may be required pursuant to Section 2(e) or Section
3(c), the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration Statement related
to the Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Holder</U>&rdquo;
or &ldquo;<U>Holders</U>&rdquo; means the holder or holders, as the case may be, from time to time of Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indemnified
Party</U>&rdquo; shall have the meaning set forth in Section 5(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indemnifying
Party</U>&rdquo; shall have the meaning set forth in Section 5(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Initial
Registration Statement</U>&rdquo; means the initial Registration Statement filed pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Losses</U>&rdquo;
shall have the meaning set forth in Section 5(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Plan
of Distribution</U>&rdquo; shall have the meaning set forth in Section 2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the
Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the
offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to
the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference
in such Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registrable
Securities</U>&rdquo; means, as of any date of determination, (a) all Shares, (b<FONT STYLE="background-color: white">) all Warrant Shares
then issued and issuable upon exercise of the Warrants (assuming on such date the Warrants are exercised in full without regard to any
exercise limitations therein), and (c</FONT>) any securities issued or then issuable upon any stock split, dividend or other distribution,
recapitalization or similar event with respect to the foregoing; <U>provided, however</U>, that any such Registrable Securities shall
cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file another, Registration
Statement hereunder with respect thereto) for so long as (x) a Registration Statement with respect to the sale of such Registrable Securities
is declared effective by the Commission under the Securities Act and such Registrable Securities have been disposed of by the Holder
in accordance with such effective Registration Statement, (y) such Registrable Securities have been previously sold in accordance with
Rule 144, or (z) such securities become eligible for resale without volume or manner-of-sale restrictions and without current public
information pursuant to Rule 144 as set forth in a written opinion letter to such effect, addressed, delivered and acceptable to the
Transfer Agent and the affected Holders (assuming that such securities and any securities issuable upon exercise, conversion or exchange
of which, or as a dividend upon which, such securities were issued or are issuable, were at no time held by any Affiliate of the Company),
as reasonably determined by the Company, upon the advice of counsel to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means any registration statement required to be filed hereunder pursuant to Section 2(a) and any additional registration
statements contemplated by Section 2(e) or Section 3(c), including (in each case) the Prospectus, amendments and supplements to any such
registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated
by reference or deemed to be incorporated by reference in any such registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
415</U>&rdquo; means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Selling
Stockholder Questionnaire</U>&rdquo; shall have the meaning set forth in Section 3(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Guidance</U>&rdquo; means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements
or requests of the Commission staff and (ii) the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Shelf Registration</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
On or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale
of all of the Registrable Securities that are not then registered on an effective Registration Statement for an offering to be made on
a continuous basis pursuant to Rule 415. Each Registration Statement filed hereunder shall be on Form S-3 (except if the Company is not
then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate
form in accordance herewith, subject to the provisions of Section 2(f)) and shall contain (unless otherwise directed by at least 85%
in interest of the Holders) substantially the &ldquo;<U>Plan of Distribution</U>&rdquo; attached hereto as <U>Annex A</U> and substantially
the &ldquo;<U>Selling Stockholder</U>&rdquo; section attached hereto as <U>Annex B</U>; <U>provided</U>, <U>however</U>, that no Holder
shall be required to be named as an &ldquo;underwriter&rdquo; without such Holder&rsquo;s express prior written consent. Subject to the
terms of this Agreement, the Company shall use its reasonable best efforts to cause a Registration Statement filed under this Agreement
(including, without limitation, under Section 3(c)) to be declared effective under the Securities Act as promptly as reasonably possible
after the filing thereof, but in any event no later than the applicable Effectiveness Date, and shall use its reasonable best efforts
to keep such Registration Statement continuously effective under the Securities Act until the earliest to occur of (i) the date that
all Registrable Securities covered by such Registration Statement (x) have been sold, thereunder or pursuant to Rule 144, or (y) may
be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance
with the current public information requirement under Rule 144, as determined by the counsel to the Company pursuant to a written opinion
letter to such effect, addressed and acceptable to the Transfer Agent and the affected Holders or (ii) the 5-year anniversary of the
date hereof (the &ldquo;<U>Effectiveness Period</U>&rdquo;). The Company shall notify the Holders of the effectiveness of the Registration
Statement on the same Trading Day as such effectiveness occurs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Notwithstanding any other provision of this Section 2, the Company shall have the right, but not the obligation, to defer the filing
of (but not the preparation of), or suspend the use by the Holders of, any Registration Statement for the shortest period reasonably
possible, (i) upon issuance by the Commission of a stop order suspending the effectiveness of such Registration Statement with respect
to Registrable Securities or the initiation of proceedings with respect to such Registration Statement under Section 9(d) or 8(e) of
the Securities Act; or (ii) if the Company believes in good faith that any such registration or offering would require the Company (after
consultation with external legal counsel), under applicable securities laws and other laws, to make disclosure of material nonpublic
information that would not otherwise be required to be disclosed at that time that would be adverse to the Company (any such period,
a &ldquo;<U>Suspension Period</U>&rdquo;); provided, that in no event shall the Company declare Suspension Periods lasting more than
120 days in the aggregate in any twelve (12) month period. The Company shall (i) give prompt written notice to the Holders of its declaration
of a Suspension Period and of the expiration or termination of the relevant Suspension Period and (ii) promptly resume the process of
filing or requesting for effectiveness, or update the suspended Registration Statement, as the case may be, as may be necessary to permit
the Holders to offer and sell their Registrable Securities in accordance with applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the Registrable
Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration
statement, the Company agrees to promptly inform each of the Holders thereof and use its commercially reasonable efforts to file amendments
to the Initial Registration Statement as required by the Commission, covering the maximum number of Registrable Securities permitted
to be registered by the Commission, on Form S-3 or such other form available to register for resale the Registrable Securities as a secondary
offering, subject to the provisions of Section 2(e); with respect to filing on Form S-3 or other appropriate form; <U>provided</U>, <U>however</U>,
that prior to filing such amendment, the Company shall be obligated to use diligent efforts to advocate with the Commission for the registration
of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, Compliance and Disclosure Interpretation
612.09.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
If: (i) the Initial Registration Statement is not filed on or prior to its Filing Date (if the Company files the Initial Registration
Statement without affording the Holders the opportunity to review and comment on the same as required by Section 3(a) herein, the Company
shall be deemed to have not satisfied this clause (i)), or (ii) the Company fails to file with the Commission a request for acceleration
of a Registration Statement in accordance with Rule 461 promulgated by the Commission pursuant to the Securities Act, within five Trading
Days of the date that the Company is notified (orally or in writing, whichever is earlier) by the Commission that such Registration Statement
will not be &ldquo;reviewed&rdquo; or will not be subject to further review, or (iii) prior to the effective date of a Registration Statement,
the Company fails to file a pre-effective amendment and otherwise respond in writing to comments made by the Commission in respect of
such Registration Statement within ten (10) calendar days after the receipt of comments by or notice from the Commission that such amendment
is required in order for such Registration Statement to be declared effective, or (iv) a Registration Statement registering for resale
all of the Registrable Securities is not declared effective by the Commission by the Effectiveness Date of the Initial Registration Statement,
or (v) after the effective date of a Registration Statement, such Registration Statement ceases for any reason to remain continuously
effective as to all Registrable Securities included in such Registration Statement, or the Holders are otherwise not permitted to utilize
the Prospectus therein to resell such Registrable Securities, for more than ten (10) consecutive calendar days or more than an aggregate
of fifteen (15) calendar days (which need not be consecutive calendar days) during any 12-month period (other than, in each case, during
the time period(s) permitted by Section 3(j)) (any such failure or breach being referred to as an &ldquo;<U>Event</U>&rdquo;, and for
purposes of clauses (i) and (iv), the date on which such Event occurs, and for purpose of clause (ii) the date on which such five (5)
Trading Day period is exceeded, and for purpose of clause (iii) the date which such ten (10) calendar day period is exceeded, and for
purpose of clause (v) the date on which such ten (10) or fifteen (15) calendar day period, as applicable, is exceeded being referred
to as &ldquo;<U>Event Date</U>&rdquo;), then, in addition to any other rights the Holders may have hereunder or under applicable law,
on each such Event Date and on each monthly anniversary of each such Event Date (if the applicable Event shall not have been cured by
such date) until the applicable Event is cured, the Company shall pay to each Holder an amount in cash, as liquidated damages and not
as a penalty, equal to the product of 2.0% multiplied by the aggregate Subscription Amount paid by such Holder pursuant to the Purchase
Agreement. The parties agree that the maximum aggregate liquidated damages payable to a Holder under this Agreement shall be 18.0% of
the aggregate Subscription Amount paid by such Holder pursuant to the Purchase Agreement. If the Company fails to pay any liquidated
damages pursuant to this Section in full within seven days after the date payable, the Company will pay interest thereon at a rate of
18% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to the Holder, accruing daily from the date
such liquidated damages are due until such amounts, plus all such interest thereon, are paid in full. The liquidated damages pursuant
to the terms hereof shall apply on a daily pro rata basis for any portion of a month prior to the cure of an Event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Notwithstanding any other provision of this Agreement, if the Commission or any SEC Guidance sets forth a limitation on the number of
Registrable Securities permitted to be registered on a particular Registration Statement as a secondary offering (and notwithstanding
that the Company used diligent efforts to advocate with the Commission for the registration of all or a greater portion of Registrable
Securities), unless otherwise directed in writing by a Holder as to its Registrable Securities, the number of Registrable Securities
to be registered on such Registration Statement will be reduced as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First,
                                            the Company shall reduce or eliminate any securities to be included other than Registrable
                                            Securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second,
                                            the Company shall reduce Registrable Securities represented by Warrant Shares (applied, in
                                            the case that some Warrant Shares may be registered, to the Holders on a pro rata basis based
                                            on the total number of unregistered Warrant Shares held by such Holders); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third,
                                            the Company shall reduce Registrable Securities represented by Shares (applied, in the case
                                            that some Shares may be registered, to the Holders on a pro rata basis based on the total
                                            number of unregistered Shares held by such Holders).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a cutback hereunder, the Company shall give the Holder at least five (5) Trading Days prior written notice along with the
calculations as to such Holder&rsquo;s allotment. In the event the Company amends the Initial Registration Statement in accordance with
the foregoing, the Company will use its best efforts to file with the Commission, as promptly as allowed by Commission or SEC Guidance
provided to the Company or to registrants of securities in general, one or more registration statements on Form S-3 or such other form
available to register for resale those Registrable Securities that were not registered for resale on the Initial Registration Statement,
as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
If Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register the
resale of the Registrable Securities on another appropriate form and (ii) undertake to register the Registrable Securities on Form S-3
as soon as such form is available, provided that the Company shall maintain the effectiveness of the Registration Statement then in effect
until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared effective by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Notwithstanding anything to the contrary contained herein, in no event shall the Company be permitted to name any Holder or affiliate
of a Holder as any Underwriter without the prior written consent of such Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Registration Procedures</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Company&rsquo;s registration obligations hereunder, the Company shall:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Not less than three (3) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day prior to
the filing of any related Prospectus or any amendment or supplement thereto (including any document that would be incorporated or deemed
to be incorporated therein by reference), the Company shall furnish to each Holder copies of all such documents proposed to be filed,
which documents (other than those incorporated or deemed to be incorporated by reference) will be subject to the review of such Holders.
The Company shall not file a Registration Statement or any such Prospectus or any amendments or supplements thereto to which the Holders
of a majority of the Registrable Securities shall reasonably object in good faith (except as is required to comply with any applicable
law or regulation), provided that, the Company is notified of such objection in writing no later than two (2) Trading Days after the
Holders have been so furnished copies of a Registration Statement or one (1) Trading Day after the Holders have been so furnished copies
of any related Prospectus or amendments or supplements thereto. Each Holder agrees to furnish to the Company a completed questionnaire
in the form attached to this Agreement as <U>Annex B</U> (a &ldquo;<U>Selling Stockholder Questionnaire</U>&rdquo;) on a date that is
not less than two (2) Trading Days prior to the Filing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
(i) Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and the Prospectus
used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the applicable Registrable
Securities for the Effectiveness Period and prepare and file with the Commission such additional Registration Statements in order to
register for resale under the Securities Act all of the Registrable Securities, (ii) cause the related Prospectus to be amended or supplemented
by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant
to Rule 424, (iii) respond to any comments received from the Commission with respect to a Registration Statement or any amendment thereto
and provide to the Holders true and complete copies of all correspondence from and to the Commission relating to a Registration Statement
(provided that, the Company shall excise any information contained therein which in good faith it believes would constitute material
non-public information regarding the Company or any of its Subsidiaries), and (iv) comply in all material respects with the applicable
provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration
Statement during the applicable period in accordance (subject to the terms of this Agreement) with the intended methods of disposition
by the Holders thereof set forth in such Registration Statement as so amended or in such Prospectus as so supplemented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
If during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common Stock
then registered in a Registration Statement, then the Company shall file as soon as reasonably practicable, but in any case prior to
the applicable Filing Date, an additional Registration Statement covering the resale by the Holders of not less than the number of such
Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Notify the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be accompanied
by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably possible
(i)(A) when a Prospectus or any Prospectus supplement or post-effective amendment to a Registration Statement is proposed to be filed,
(B) when the Commission notifies the Company whether there will be a &ldquo;review&rdquo; of such Registration Statement and whenever
the Commission comments in writing on such Registration Statement, and (C) with respect to a Registration Statement or any post-effective
amendment, when the same has become effective, (ii) of any request by the Commission or any other federal or state governmental authority
for amendments or supplements to a Registration Statement or Prospectus or for additional information, (iii) of the issuance by the Commission
or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement covering
any or all of the Registrable Securities or the initiation of any Proceedings for that purpose, (iv) of the receipt by the Company of
any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities
for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose, and (v) of the occurrence of any event
or passage of time that makes the financial statements included in a Registration Statement ineligible for inclusion therein or any statement
made in a Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue
in any material respect or that requires any revisions to a Registration Statement, Prospectus or other documents so that, in the case
of a Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit
to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Use its best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending the effectiveness
of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable
Securities for sale in any jurisdiction, at the earliest practicable moment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Furnish to each Holder, without charge, at least one conformed copy of each such Registration Statement and each amendment thereto, including
financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the extent requested
by such Person, and all exhibits to the extent requested by such Person (including those previously furnished or incorporated by reference)
promptly after the filing of such documents with the Commission, provided that any such item which is available on the EDGAR system (or
successor thereto) need not be furnished in physical form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement thereto
by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and
any amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
If requested by a Holder and to the extent the Company has certificated shares of Common Stock, cooperate with such Holder to facilitate
the timely preparation and delivery of certificates representing Registrable Securities to be delivered to a transferee pursuant to a
Registration Statement, which certificates shall be free, to the extent permitted by the Purchase Agreement, of all restrictive legends,
and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holder may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Upon the occurrence of any event contemplated by Section 3(d), as promptly as reasonably possible under the circumstances taking into
account the Company&rsquo;s good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure
of such event, prepare a supplement or amendment, including a post-effective amendment, to a Registration Statement or a supplement to
the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document
so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will contain an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading. If the Company notifies the Holders in accordance with clauses (iii) through (vi) of Section
3(d) above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall
suspend use of such Prospectus. The Company will use its reasonable efforts to ensure that the use of the Prospectus may be resumed as
promptly as is reasonably practicable. </FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">(j)
Otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the Commission under the Securities
Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus, including any
supplement or amendment thereof, with the Commission pursuant to Rule 424 under the Securities Act, promptly inform the Holders in writing
if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof,
the Holders are required to deliver a Prospectus in connection with any disposition of Registrable Securities and take such other actions
as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder.</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">(k)
The Company shall use its reasonable best efforts to maintain eligibility for use of Form S-3 (or any successor form thereto) for the
registration of the resale of Registrable Securities.</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">(l)
The Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common Stock
beneficially owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and dispositive control
over the shares. During any periods that the Company is unable to meet its obligations hereunder with respect to the registration of
the Registrable Securities solely because any Holder fails to furnish such information within three Trading Days of the Company&rsquo;s
request, any liquidated damages that are accruing at such time as to such Holder only shall be tolled and any Event that may otherwise
occur solely because of such delay shall be suspended as to such Holder only, until such information is delivered to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Registration Expenses</U>. All fees and expenses incident to the performance of or compliance with, this Agreement by the Company
shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses
referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation,
fees and expenses of the Company&rsquo;s counsel and independent registered public accountants) (A) with respect to filings made with
the Commission, (B) with respect to filings required to be made with any Trading Market on which the Common Stock is then listed for
trading, and (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including,
without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of the
Registrable Securities), (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities),
(iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability
insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection
with the consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its
internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without
limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual
audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required
hereunder. In no event shall the Company be responsible for any broker or similar commissions of any Holder or, except to the extent
provided for in the Transaction Documents, any legal fees or other costs of the Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Indemnification by the Company</U>. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless
each Holder, the officers, directors, members, partners, and employees (and any other Persons with a functionally equivalent role of
a Person holding such titles, notwithstanding a lack of such title or any other title) of each of them, and each Person who controls
any such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) as well as their respective
officers, directors, members, stockholders, partners, agents and employees (and any other Persons with a functionally equivalent role
of such Person holding such titles, notwithstanding a lack of such title or any other title) of each such controlling Person, to the
fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without
limitation, reasonable attorneys&rsquo; fees) and expenses (collectively, &ldquo;<U>Losses</U>&rdquo;), as incurred, arising out of or
relating to (1) any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any Prospectus or any
form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission
or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading or (2)
any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or
regulation thereunder, in connection with the performance of its obligations under this Agreement (clauses 1 and 2 collectively &ldquo;<U>Company
Violations</U>&rdquo;); <U>provided</U>, <U>however</U>, that the indemnification in this Section 5(a)(i) shall not apply to any Loss
arising out of or based upon any Company Violation which occurs in reliance upon information furnished in writing to the Company by or
on behalf of a Holder expressly for use therein, or to the extent that such information relates to a Holder or a Holder&rsquo;s proposed
method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use
therein (it being understood that the Holder has approved Annex A hereto for this purpose), (ii) with respect to any superseded prospectus,
shall not inure to the benefit of any such Person from whom the Person asserting any such Loss purchased the Registrable Securities that
are the subject thereof if the untrue statement or omission of material fact contained in the superseded prospectus was corrected in
the revised prospectus, as then amended or supplemented and the applicable Person was advised in writing not to use the incorrect prospectus
prior to the use giving rise to a violation, and (iii) shall not be available to the extent such Loss is based on a failure of a Holder
to deliver, or to cause to be delivered, the prospectus made available by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Indemnification by Holders</U>. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors,
officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section
20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted
by applicable law, from and against all Losses, as incurred, to the extent arising out of or based upon: (1) any untrue or alleged untrue
statement of a material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement thereto or in
any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated
therein or necessary to make the statements therein not misleading (i) to the extent that such untrue statement or omission is contained
in any information so furnished in writing by or on behalf of such Holder to the Company expressly for inclusion in such Registration
Statement or such Prospectus or (ii) to the extent that such information relates to such Holder&rsquo;s information provided in the Selling
Stockholder Questionnaire or the proposed method of distribution of Registrable Securities and was reviewed and expressly approved in
writing by such Holder expressly for use in a Registration Statement (it being understood that the Holder has approved Annex A hereto
for this purpose), such Prospectus or in any amendment or supplement thereto or (2) any violation or alleged violation by the Holder
of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder. In no event shall the liability
of a selling Holder be greater in amount than the dollar amount of the proceeds received by such Holder upon the sale of the Registrable
Securities included in the Registration Statement giving rise to such indemnification obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Conduct of Indemnification Proceedings</U>. If any Proceeding shall be brought or asserted against any Person entitled to indemnity
hereunder (an &ldquo;<U>Indemnified Party</U>&rdquo;), such Indemnified Party shall promptly notify the Person from whom indemnity is
sought (the &ldquo;<U>Indemnifying Party</U>&rdquo;) in writing, and the Indemnifying Party shall have the right to assume the defense
thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses
incurred in connection with defense thereof, provided that the failure of any Indemnified Party to give such notice shall not relieve
the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be
finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure
shall have materially and adversely prejudiced the Indemnifying Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but
the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party
has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the defense of such
Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to
any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and counsel to
the Indemnified Party shall reasonably believe that a material conflict of interest exists if the same counsel were to represent such
Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that
it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume
the defense thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying
Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which
consent shall not be unreasonably withheld or delayed. No Indemnifying Party shall, without the prior written consent of the Indemnified
Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes
an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms of this Agreement, all reasonable and documented out of pocket fees and expenses of the Indemnified Party shall be paid
to the Indemnified Party, as incurred, within ten Trading Days of written notice thereof to the Indemnifying Party, provided that the
Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such actions
for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject to appeal
or further review) not to be entitled to indemnification hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Contribution</U>. If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold
an Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified
Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection
with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative
fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in
question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has
been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties&rsquo; relative
intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or
payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any
reasonable attorneys&rsquo; or other fees or expenses incurred by such party in connection with any Proceeding to the extent such party
would have been indemnified for such fees or expenses if the indemnification provided for in this Section was available to such party
in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata
allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately
preceding paragraph. In no event shall the contribution obligation of a Holder of Registrable Securities be greater in amount than the
dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the
amount of any damages such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission
or alleged omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have
to the Indemnified Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Remedies</U>. In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement,
each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement,
including recovery of damages, shall be entitled to specific performance of its rights under this Agreement. Each of the Company and
each Holder agrees that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it
of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect
of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>No Piggyback on Registrations</U>. Neither the Company nor any of its security holders (other than the Holders in such capacity pursuant
hereto) may include securities of the Company in any Registration Statements other than the Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Discontinued Disposition</U>. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from
the Company of the occurrence of any event of the kind described in Section 3(d)(iii) through (v), such Holder will forthwith discontinue
disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the &ldquo;<U>Advice</U>&rdquo;)
by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Amendments and Waivers</U>. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified
or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing
and signed by the Company and the Holders of 50.1% or more of the then outstanding Registrable Securities (for purposes of clarification,
this includes any Registrable Securities issuable upon exercise or conversion of any Security), provided that, if any amendment, modification
or waiver disproportionately and adversely impacts a Holder (or group of Holders), the consent of such disproportionately impacted Holder
(or group of Holders) shall be required. If a Registration Statement does not register all of the Registrable Securities pursuant to
a waiver or amendment done in compliance with the previous sentence, then the number of Registrable Securities to be registered for each
Holder shall be reduced pro rata among all Holders and each Holder shall have the right to designate which of its Registrable Securities
shall be omitted from such Registration Statement. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof
with respect to a matter that relates exclusively to the rights of a Holder or some Holders and that does not directly or indirectly
affect the rights of other Holders may be given only by such Holder or Holders of all of the Registrable Securities to which such waiver
or consent relates; <U>provided</U>, <U>however</U>, that the provisions of this sentence may not be amended, modified, or supplemented
except in accordance with the provisions of the first sentence of this Section 6(d). No consideration shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration also is offered
to all of the parties to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered
as set forth in the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Successors and Assigns</U>. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns
of each of the parties and shall inure to the benefit of each Holder. No party may assign (except by merger) its rights or obligations
hereunder without the prior written consent of the other parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Execution and Counterparts</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall
be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to
the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered
by facsimile transmission or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding
obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile
or &ldquo;.pdf&rdquo; signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be
determined in accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Cumulative Remedies</U>. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Headings</U>. The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall not be
deemed to limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Independent Nature of Holders&rsquo; Obligations and Rights</U>. The obligations of each Holder hereunder are several and not joint
with the obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations
of any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action
taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint venture
or any other kind of group or entity, or create a presumption that the Holders are in any way acting in concert or as a group or entity
with respect to such obligations or the transactions contemplated by this Agreement or any other matters, and the Company acknowledges
that the Holders are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations
or transactions. Each Holder shall be entitled to protect and enforce its rights, including without limitation the rights arising out
of this Agreement, and it shall not be necessary for any other Holder to be joined as an additional party in any proceeding for such
purpose. The use of a single agreement with respect to the obligations of the Company contained was solely in the control of the Company,
not the action or decision of any Holder, and was done solely for the convenience of the Company and not because it was required or requested
to do so by any Holder. It is expressly understood and agreed that each provision contained in this Agreement is between the Company
and a Holder, solely, and not between the Company and the Holders collectively and not between and among Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Abeona
    Therapeutics Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGE OF HOLDERS FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
PAGE OF HOLDERS TO RRA]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Holder: __________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Holder</I>: __________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: __________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Annex
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Plan
of Distribution</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Selling Stockholder (the &ldquo;<U>Selling Stockholders</U>&rdquo;) of the securities and any of their pledgees, assignees and successors-in-interest
may, from time to time, sell any or all of their securities covered hereby on the principal Trading Market or any other stock exchange,
market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices.
A Selling Stockholder may use any one or more of the following methods when selling securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
    brokerage transactions and transactions in which the broker-dealer solicits purchasers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
    trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block
    as principal to facilitate the transaction;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
    by a broker-dealer as principal and resale by the broker-dealer for its account;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    exchange distribution in accordance with the rules of the applicable exchange;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately
    negotiated transactions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">settlement
    of short sales;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated
    price per security;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
    the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    combination of any such methods of sale; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other method permitted pursuant to applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;), if available, rather than under this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker-dealers
engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or
markdown in compliance with FINRA Rule 2121.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they
assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan
or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option
or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the
delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &ldquo;underwriters&rdquo;
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company
has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders
without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for
the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar
effect or (ii) the date on which all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act
or any other rule of similar effect, (iii) [Insert date that is [2 years] after the date of the Registration Rights Agreement], or (iv)
a Change of Control (as defined in the Registration Rights Agreement). The resale securities will be sold only through registered or
licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities
covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the
registration or qualification requirement is available and is complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously
engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M,
prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the
Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the
common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders
and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including
by compliance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SELLING
SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock being offered by the selling shareholders are those previously issued to the selling shareholders, and those issuable to
the selling shareholders, upon exercise of the warrants. For additional information regarding the issuances of those shares of common
stock and warrants, see &ldquo;Private Placement of Shares of Common Stock and Warrants&rdquo; above. We are registering the shares of
common stock in order to permit the selling shareholders to offer the shares for resale from time to time. Except for the ownership of
the shares of common stock and the warrants, the selling shareholders have not had any material relationship with us within the past
three years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below lists the selling shareholders and other information regarding the beneficial ownership of the shares of common stock by
each of the selling shareholders. The second column lists the number of shares of common stock beneficially owned by each selling shareholder,
based on its ownership of the shares of common stock and warrants, as of ________, 2022, assuming exercise of the warrants held by the
selling shareholders on that date, without regard to any limitations on exercises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
third column lists the shares of common stock being offered by this prospectus by the selling shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the terms of a registration rights agreement with the selling shareholders, this prospectus generally covers the resale
of the sum of (i) the number of shares of common stock issued to the selling shareholders in the &ldquo;Private Placement of Shares of
Common Stock and Warrants&rdquo; described above <FONT STYLE="background-color: white">and (ii) the maximum number of shares of common
stock issuable upon exercise of the related warrants, determined as if the outstanding warrants were exercised in full as of the trading
day immediately preceding the date this registration statement was initially filed with the SEC, each as of the trading day immediately
preceding the applicable date of determination and all subject to adjustment as provided in the registration right agreement, without
regard to any limitations on the exercise of the warrants</FONT>. The fourth column assumes the sale of all of the shares offered by
the selling shareholders pursuant to this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the terms of the warrants, a selling shareholder may not exercise the warrants to the extent such exercise would cause such selling shareholder,
together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99%
or 9.99%, as applicable, of our then outstanding common stock following such exercise, excluding for purposes of such determination shares
of common stock issuable upon exercise of such warrants which have not been exercised. The number of shares in the second and fourth
columns do not reflect this limitation.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The selling shareholders
may sell all, some or none of their shares in this offering. See &ldquo;Plan of Distribution.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of Selling Shareholder</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Shares of Common Stock Owned Prior to Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Shares of Common Stock to be Sold Pursuant to this Prospectus</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Shares of Common Stock Owned After Offering</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Annex
C</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>COMPANY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selling
Stockholder Notice and Questionnaire</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned beneficial owner of common stock (the &ldquo;<U>Registrable Securities</U>&rdquo;) of Abeona Therapeutics Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), understands that the Company has filed or intends to file with the Securities and Exchange
Commission (the &ldquo;<U>Commission</U>&rdquo;) a registration statement (the &ldquo;<U>Registration Statement</U>&rdquo;) for the registration
and resale under Rule 415 of the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), of the Registrable Securities,
in accordance with the terms of the Registration Rights Agreement (the &ldquo;<U>Registration Rights Agreement</U>&rdquo;) to which this
document is annexed. A copy of the Registration Rights Agreement is available from the Company upon request at the address set forth
below. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
legal consequences arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly,
holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences
of being named or not being named as a selling stockholder in the Registration Statement and the related prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned beneficial owner (the &ldquo;<U>Selling Stockholder</U>&rdquo;) of Registrable Securities hereby elects to include the Registrable
Securities owned by it in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QUESTIONNAIRE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Name.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Full Legal Name of Selling Stockholder</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to
vote or dispose of the securities covered by this Questionnaire):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
<U>Address for Notices to Selling Stockholder</U>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">________________________________________________________________________________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">________________________________________________________________________________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">________________________________________________________________________________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
_______________________________________________________________________________________   </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax:
    </FONT>____________________________________________________________________________________________</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contact
    Person: _______________________________________________________________________________</FONT>____</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
<U>Broker-Dealer Status</U>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Are you a broker-dealer?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: right; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes &#9744;</FONT></TD><TD STYLE="width: 8%"></TD><TD STYLE="text-align: justify; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> No &#9744;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 180.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If &ldquo;yes&rdquo; to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to
the Company?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 41%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes &#9744;</FONT></TD><TD STYLE="width: 8%"></TD><TD STYLE="text-align: justify; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> No &#9744;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 180.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            &ldquo;no&rdquo; to Section 3(b), the Commission&rsquo;s staff has indicated that you should
                                            be identified as an underwriter in the Registration Statement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -35.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Are you an affiliate of a broker-dealer?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 41%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes &#9744;</FONT></TD><TD STYLE="width: 8%"></TD><TD STYLE="text-align: justify; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> No &#9744;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 180.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business,
and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly,
with any person to distribute the Registrable Securities?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 41%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT> &#9744;</TD><TD STYLE="width: 8%"></TD><TD STYLE="text-align: justify; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> No &#9744;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 180.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            &ldquo;no&rdquo; to Section 3(d), the Commission&rsquo;s staff has indicated that you should
                                            be identified as an underwriter in the Registration Statement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -35.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
<U>Beneficial Ownership of Securities of the Company Owned by the Selling Stockholder</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Except
as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than
the securities issuable pursuant to the Purchase Agreement.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Type and Amount of other securities beneficially owned by the Selling Stockholder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
<U>Relationships with the Company</U>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Except
as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5%
of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with
the Company (or its predecessors or affiliates) during the past three years.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -35.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
any exceptions here:</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned agrees to promptly notify the Company of any material inaccuracies or changes in the information provided herein that may
occur subsequent to the date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall
not be required to notify the Company of any changes to the number of securities held or owned by the undersigned or its affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and
the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto.
The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment
of the Registration Statement and the related prospectus and any amendments or supplements thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either
in person or by its duly authorized agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 43%">&nbsp;</TD><TD STYLE="width: 2%"></TD><TD STYLE="text-align: left; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial Owner:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%"></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 234.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLEASE
FAX A COPY (OR EMAIL A .PDF COPY) OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE TO:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 24; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of November 3, 2022 (the &ldquo;<U>Effective Date</U>&rdquo;),
between Abeona Therapeutics Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature
pages hereto (each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively, the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act (as defined below),
and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly,
desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
I.<BR>
DEFINITIONS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1 <U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings
set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <FONT STYLE="background-color: white"><U>provided</U>, <U>however</U>, for clarification, commercial
banks shall not be deemed to be authorized or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;,
&ldquo;non-essential employee&rdquo; or any other similar orders or restrictions or the closure of any physical branch locations at the
direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial
banks in The City of New York generally are open for use by customers on such day</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the date on which the Closing occurs, which shall not be later than two Trading Days after the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Common
Warrant Shares</U><FONT STYLE="background-color: white">&rdquo; means the shares of Common Stock issuable upon exercise of the Common
Warrants.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Common
Warrants</U><FONT STYLE="background-color: white">&rdquo; means, collectively, the Common Stock purchase warrants delivered to the Purchasers
at the Closing in accordance with Section 2.2(a) hereof, which Warrants shall be in the form of </FONT><U>Exhibit A</U> <FONT STYLE="background-color: white">attached
hereto.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Willkie Farr and Gallagher LLP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the
date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant
to any stock or option plan or similar plan or program, duly adopted for such purpose, by a majority of the non-employee members of the
Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered
to the Company, or the sale of shares of Common Stock on behalf of officers or directors in order to satisfy tax obligations in connection
with the vesting of equity compensation grants, (b) warrants to the Placement Agent in connection with the transactions pursuant to this
Agreement and any securities upon exercise of warrants to the Placement Agent, securities upon the exercise or exchange of or conversion
of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock
issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement
to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other
than in connection with stock splits or combinations) or to extend the term of such securities and (c) securities issued pursuant to
acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities
are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit the
filing of any registration statement in connection therewith during the prohibition period in Section 4.10(a) herein, and provided that
any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating
company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional
benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily
for the purpose of raising capital or to an entity whose primary business is investing in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Fundamental
Representations</U>&rdquo; means the representations set forth in Sections 3.1(b), 3.1(c), 3.1(d)(i), 3.1(f), 3.1(g), 3.1(t) and 3.2(a)-(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Legend
Removal Date</U>&rdquo; shall have the meaning ascribed to such term in Section 4.1(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Lock-Up
Agreement</U>&rdquo; means the Lock-Up Agreement, dated as of the date hereof, by and among the Company and the Company&rsquo;s directors
and officers, in the form of <U>Exhibit B</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>knowledge
</U>or <U>Knowledge</U>&rdquo; of the Company means the actual knowledge, without duty of inquiry of the Chief Executive Officer, Chief
Financial Officer and General Counsel of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agent</U>&rdquo; means Cantor Fitzgerald &amp; Co.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing in
accordance with Section 2.2(a) hereof, in the form of <U>Exhibit C</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Rights Agreement</U>&rdquo; means the Registration Rights Agreement, dated on or about the date hereof, among the Company and the Purchasers,
in the form of <U>Exhibit D</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means a registration statement meeting the requirements set forth in the Registration Rights Agreement and covering
the resale by the Purchasers of the Shares and the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Securities</U><FONT STYLE="background-color: white">&rdquo;
means the Shares, the Warrants and the Warrant Shares.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified
below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo;
in United States dollars and in immediately available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants, the Registration Rights Agreement, the Lock-Up Agreement, all exhibits and schedules
thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means American Stock Transfer &amp; Trust Company, LLC, the current transfer agent of the Company, and any successor
transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.10(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Warrants</U><FONT STYLE="background-color: white">&rdquo;
means, collectively, the Common Warrants and the Pre-Funded Warrants.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Warrant
Shares</U><FONT STYLE="background-color: white">&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
II.<BR>
PURCHASE AND SALE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1 <U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery
of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase,
up to an aggregate of $35,000,002 of Shares and Warrants. In each case, the election to receive Pre-Funded Warrants is solely at the
option of the Purchaser. Each Purchaser shall deliver to the Company, via wire transfer or a certified check, immediately available funds
equal to such Purchaser&rsquo;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser, and the Company
shall deliver to each Purchaser its respective Shares and a Warrant, as determined pursuant to Section 2.2(a), and the Company and each
Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions
set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of the Company or such other location as the parties shall
mutually agree.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2 <U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) this
Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) a
legal opinion of Company Counsel in the form provided to the Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) a
copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver, on an expedited basis, a certificate
evidencing a number of Shares equal to the number of shares <FONT STYLE="background-color: white">registered in the name of such Purchaser
as set forth on the signature page of such Purchaser</FONT>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) <FONT STYLE="background-color: white">if
applicable, a Pre-Funded Warrant registered in the name of such Purchaser for the number of shares set forth on the signature page of
such Purchaser;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) <FONT STYLE="background-color: white">a
Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of the sum of such
Purchaser&rsquo;s Shares and Pre-Funded Warrant Shares, with an exercise price equal to $4.75 per share, subject to adjustment therein,
which shall have a term of five (5) years and shall be in the form of </FONT><U>Exhibit A</U> <FONT STYLE="background-color: white">attached
hereto;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi) the
Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company letterhead and executed by an officer
of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii) the
Lock-Up Agreements; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii) the
Registration Rights Agreement duly executed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) this
Agreement duly executed by such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) such
Purchaser&rsquo;s Subscription Amount by wire transfer to the account specified by the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) the
Registration Rights Agreement duly executed by such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3 <U>Closing
Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific
date therein in which case they shall be accurate as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) the
delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) the
accuracy when made and on the Closing Date (unless as of a specific date therein in which case they shall be accurate as of such date)
of the representations and warranties of the Company contained herein (without giving effect to any materiality or Material Adverse Effect
qualification therein) in each case except where such in accuracy would not, and would reasonably be expected to, result in a Material
Adverse Effect;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) there
shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
III.<BR>
REPRESENTATIONS AND WARRANTIES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 <U>Representations
and Warranties of the Company</U>. The Company hereby makes the following representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. Except as set forth in the SEC Reports,
the Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any
Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable
and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references
to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority
to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary
is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, would not have or reasonably be expected
to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material
adverse effect on the results of operations, assets, business or condition (financial or otherwise) of the Company and the Subsidiaries,
taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis
its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;); provided
that, for purposes of clause (ii), the following shall not be deemed a Material Adverse Effect: (I) any adverse effect on the economic
condition or financial markets general, or of the industry in which the Company operates, (II) the outbreak or worsening of any war,
hostility or conflict, or (III) the occurrence or worsening of any natural disaster, fire, storm, flood, disease outbreak, pandemic or
epidemic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith other
than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or
upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which
it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (i), (ii)
and (iii), such as would not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) <U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in
connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required
pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission pursuant to the Registration Rights Agreement, (iii) the
notice and/or application(s) to each applicable Trading Market for the issuance and sale of the Securities and the listing of the Shares
and Warrant Shares for trading thereon in the time and manner required thereby and (iv) the filing of Form D with the Commission and
such filings as are required to be made under applicable state securities laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) <U>Issuance
of the Securities</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than
restrictions on transfer provided for in the Transaction Documents or imposed by applicable securities laws. The <FONT STYLE="background-color: white">Warrant
Shares, when issued in accordance with the terms of the Transaction Documents, will be validly issued, fully paid and nonassessable,
free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in the Transaction Documents or imposed
by applicable securities laws. The</FONT> Company has duly authorized capital stock sufficient to issue the maximum number of shares
of Common Stock issuable pursuant to this Agreement and the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) <U>Capitalization</U>.
The authorized capitalization of the Company is as set forth in the SEC Reports. No Person has any right of first refusal, preemptive
right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except
as a result of the purchase and sale of the Securities or pursuant to the Company&rsquo;s equity incentive plan, outstanding warrants
disclosed in the SEC Reports or other Exempt Issuances, there are no outstanding options, warrants, calls or commitments of any character
whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person
any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary. The issuance and sale of the
Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than
the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts
the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any
Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar
plan or agreement. No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance
and sale of the Securities. Other than as set forth in the SEC Reports, there are no stockholders agreements, voting agreements or other
similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company,
between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h) <U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two
years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein
as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received a valid extension of such time of filing and has filed any
such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material
respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained
any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not materially misleading. The Company has never
been an issuer subject to Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports comply
in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto
as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted
accounting principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise
specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes
required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries
as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited
statements, to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) <U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included within
the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof: (i) there has been no event,
occurrence or development that has had or that would reasonably be expected to result in a Material Adverse Effect, (ii) the Company
has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary
course of business consistent with past practice and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements
pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not materially altered its method of accounting,
(iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed
or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities
to any officer, director or Affiliate, except pursuant to existing Company stock option plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j) <U>Litigation</U>.
There is no action, suit, inquiry, notice of violation or proceeding pending or, to the knowledge of the Company, threatened against
or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative
agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;) that (i) adversely
affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) would, if
there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any
Subsidiary, nor any director or officer thereof (in their capacity as such), is or has been the subject of any Action involving a claim
of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to
the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any
current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness
of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k) <U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which would reasonably be expected to result in a Material Adverse Effect. To the knowledge of the Company, no executive officer of the
Company or any Subsidiary is, or is now expected to be, in violation of any material term of any employment contract, confidentiality,
disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant
in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries
to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal,
state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and
wages and hours, except where the failure to be in compliance would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l) <U>Compliance</U>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default
or violation has been waived), (ii) is in violation of any judgment, decree, or order of any court, arbitrator or other governmental
authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including
without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety,
product quality and safety and employment and labor matters, except in each case as would not have or reasonably be expected to result
in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m) <U>Environmental
Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata),
including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating to
the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as
all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have
received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and
(iii), the failure to so comply would be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n) <U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits would not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o) <U>Title
to Assets</U>. Except as disclosed in the SEC Reports, the Company and the Subsidiaries have good and marketable title in fee simple
to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business
of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value
of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries,
and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance
with GAAP and the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease
by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries
are in compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p) <U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to
so have would have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None of, and neither
the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired,
terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement,
in each case as would have or reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary has received,
since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has
any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as would not have or reasonably
be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable
and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries
have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except
where failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q) <U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not
limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any
Subsidiary has received notice that it will not be able to renew its existing insurance coverage as and when such coverage expires or
to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r) <U>Transactions
with Affiliates and Employees</U>. None of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company,
none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other
than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing
of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending
of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any
entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder,
member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered,
(ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements
under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s) <U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with all applicable requirements of the Sarbanes-Oxley
Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission
thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a system of
internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&rsquo;s
general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with GAAP and to maintain asset accountability, and (iii) access to assets is permitted only in accordance with management&rsquo;s general
or specific authorization. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure
that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed,
summarized and reported, within the time periods specified in the Commission&rsquo;s rules and forms. The Company&rsquo;s certifying
officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end
of the period covered by the most recently filed periodic report under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t) <U>Certain
Fees</U>. Other than fees payable to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions are or will be payable by
the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other
Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect
to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that
may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u) <U>Private
Placement</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, no registration
under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated hereby.
The issuance and sale of the Shares hereunder does not contravene the rules and regulations of the Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) <U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be
or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The
Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w) <U>Registration
Rights</U>. Other than each of the Purchasers, no Person has any right to cause the Company or any Subsidiary to effect the registration
under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x) <U>Listing
and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company
has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common
Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration.
Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received notice from any Trading
Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing
or maintenance requirements of such Trading Market. The Company is, and, other than as disclosed in the SEC Reports, has no reason to
believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.
The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation
and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in
connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y) <U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or would become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their
obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s
issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z) <U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, neither
the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or
sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of any
such securities under the Securities Act, or (ii) any applicable shareholder approval provisions of any Trading Market on which any of
the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa) <U>Tax
Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material
Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all
foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid
all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns,
reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for
periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount
claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis
for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb) <U>No
General Solicitation</U>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Securities
by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchasers and
certain other &ldquo;accredited investors&rdquo; within the meaning of Rule 501 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc) <U>Foreign
Corrupt Practices.</U> Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to
foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds,
(iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of
which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd) <U>Accountants</U>.
The Company&rsquo;s accounting firm is set forth in the SEC Reports. To the knowledge of the Company, such accounting firm (i) is a registered
public accounting firm as required by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to
be included in the Company&rsquo;s Annual Report for the fiscal year ending December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee) <U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers is acting solely
in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby.
The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their
respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely
incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff) <U>Regulation
M Compliance.</U> The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action
designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities,
or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company,
other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg) <U>FDA</U>.
As to each (ii) product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) under the Federal Food,
Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;FDCA&rdquo;) that is manufactured, packaged, labeled, tested
and/or distributed by the Company or any of its Subsidiaries (each such product, a &ldquo;Pharmaceutical Product&rdquo;), such Pharmaceutical
Product is being manufactured, packaged, labeled, tested and/or distributed by the Company in compliance with all applicable requirements
under FDCA and similar laws, rules and regulations relating to registration, investigational use, licensure, or application approval,
good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record
keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. Except as disclosed
in the SEC Reports, there is no pending, completed or, to the Company&rsquo;s knowledge, threatened, action (including any lawsuit, arbitration,
or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries,
and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any
other governmental entity, which (i) contests the licensure, registration, or approval of, the uses of, the distribution of, the manufacturing
or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval
of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials
relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries,
(iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree
of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations
by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect.
The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with
all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing,
sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA
expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh) <U>Form
S-3 Eligibility</U>. The Company is eligible to register the resale of the Securities for resale by the Purchaser on Form S-3 promulgated
under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) <U>Stock
Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the
Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the
Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj) <U>Cybersecurity</U>.
(i)(x) To the Company&rsquo;s knowledge there has been no security breach or other compromise of or relating to any of the Company&rsquo;s
or any Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data (including the data of its
respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology
(collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not been notified of, and has
no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise to its
IT Systems and Data, in each case of clauses (x) and (y) that have or would, individually or in the aggregate, reasonably be expected
to result in a Material Adverse Effect; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or
statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal
policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems
and Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have
a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards
to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of all
IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with
industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk) <U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll) <U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm) <U>Solvency</U>.
After giving effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder, the Company has no knowledge
of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn) <U>Other
Covered Persons</U>. Other than the Placement Agents, the Company is not aware of any person (other than any Issuer Covered Person) that
has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo) <U>No
Disqualification Events</U>. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under the Securities
Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company
participating in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s outstanding voting equity securities,
calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with
the Company in any capacity at the time of sale (each, an &ldquo;<U>Issuer Covered Person</U>&rdquo; and, together, &ldquo;<U>Issuer
Covered Persons</U>&rdquo;) is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications described in Rule 506(d)(1)(i) to (viii)
under the Securities Act (a &ldquo;<U>Disqualification Event</U>&rdquo;), except for a Disqualification Event covered by Rule 506(d)(2)
or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification
Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the
Purchasers a copy of any disclosures provided thereunder upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2 <U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the
date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate
as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Organization;
Authority</U>. Such Purchaser is an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction
of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to
enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder
and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated
by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar
action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such
Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation
of such Purchaser, enforceable against it in accordance with its terms, except (i) as limited by general equitable principles and applicable
bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights
generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies
and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Own
Account</U>. Such Purchaser understands that the Securities are &ldquo;restricted securities&rdquo; and have not been registered under
the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account and not with
a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state
securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable
state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the
distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty
not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with
applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which
it exercises any Warrants, it will be either: (i) an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3),
(a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act or (ii) a &ldquo;qualified institutional buyer&rdquo; as defined
in Rule 144A(a) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) <U>General
Solicitation</U>. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at
any seminar or any other general solicitation or general advertisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) <U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results
of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither the Placement
Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the Securities
nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate of the Placement Agent has made
or makes any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired
non-public information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance
of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary
to such Purchaser. Nothing in this Section 3.2(f) shall affect the Holder&rsquo;s right to rely on the representations and warranties
of the Company in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) <U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or
sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first
received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms
of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the
case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other
portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets
managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to
other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers, directors,
partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures
made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing,
for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect
to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
IV.<BR>
OTHER AGREEMENTS OF THE PARTIES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1 <U>Transfer
Restrictions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The
Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities
other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser, the Company
may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable
to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer
does not require registration of such transferred Securities under the Securities Act. As a condition of transfer, any such transferee
shall agree in writing to be bound by the terms of this Agreement and the Registration Rights Agreement and shall have the rights and
obligations of a Purchaser under this Agreement and the Registration Rights Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities in the following
form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON
AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY
NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE
SECURITIES LAWS. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER
LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR
OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Certificates
evidencing the Shares and Warrant Shares shall not contain any legend (including the legend set forth in Section 4.1(b) hereof), (i)
while a registration statement (including the Registration Statement) covering the resale of such security is effective under the Securities
Act, (ii) following any sale of such Shares or Warrant Shares pursuant to Rule 144, (iii) if such Shares or Warrant Shares are eligible
for sale under Rule 144, or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial
interpretations and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal opinion
to the Transfer Agent or the Purchaser if required by the Transfer Agent to effect the removal of the legend hereunder, or if requested
by a Purchaser, respectively. <FONT STYLE="background-color: white">If all or any portion of a Warrant is exercised at a time when there
is an effective registration statement to cover the resale of the Warrant Shares, or if such Shares or Warrant Shares may be sold under
Rule 144 and the Company is then in compliance with the current public information required under Rule 144 (assuming cashless exercise
of the Warrants), or if the Shares or Warrant Shares may be sold under Rule 144 without the requirement for the Company to be in compliance
with the current public information required under Rule 144 as to such Shares or Warrant Shares or if such legend is not otherwise required
under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the
Commission) then such Warrant Shares shall be issued free of all legends.</FONT> The Company agrees that at such time as such legend
is no longer required under this Section 4.1(c), it will, no later than the earlier of (i) two (2) Trading Days and (ii) the number of
Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company or the
Transfer Agent of a certificate representing Shares or Warrant Shares, as the case may be, issued with a restrictive legend (such date,
the &ldquo;<U>Legend Removal Date</U>&rdquo;), deliver or cause to be delivered to such Purchaser a certificate representing such shares
that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the
Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4. Certificates for Securities subject to legend removal
hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting the account of the Purchaser&rsquo;s prime broker
with the Depository Trust Company System as directed by such Purchaser. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of a certificate representing Shares or Warrant Shares, as the case may be,
issued with a restrictive legend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) Each
Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will sell any Securities
pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or
an exemption therefrom, and that if Securities are sold pursuant to a Registration Statement, they will be sold in compliance with the
plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing Securities
as set forth in this Section 4.1 is predicated upon the Company&rsquo;s reliance upon this understanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2 <U>Furnishing
of Information; Public Information</U>. Until the earlier of the time that (i) no Purchaser owns Securities or (ii) the Common Warrants
have expired, the Company covenants to maintain the registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act
and to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed
by the Company after the date hereof pursuant to the Exchange Act for so long as the Company is subject to the reporting requirements
of the Exchange Act. Notwithstanding the foregoing, nothing in this Section 4.2 will prevent the Company from pursuing and completing
an acquisition of the Company pursuant to which, as a result of the completion of any such acquisition, the Common Stock is no longer
registered under Section 12(b) or 12(g) of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 <U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in
Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the
registration under the Securities Act of the sale of the Securities or that would be integrated with the offer or sale of the Securities
for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing
of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4 <U>Securities
Laws Disclosure; Publicity</U>. The Company shall by the Disclosure Time, (a) issue a press release disclosing the material terms of
the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto,
with the Commission. From and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly
disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of
their respective officers, directors, employees or agents in connection with the transactions contemplated by the Transaction Documents.
In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality
or similar obligations under any agreement entered into in connection with the transactions contemplated by this Agreement (whether written
or oral), between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates
on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. Nor Purchaser shall issue any
such press release nor otherwise make any such public statement regarding the transaction contemplated by this Agreement without the
prior consent of the Company, except if such disclosure is required by law, in which case the disclosing party shall promptly provide
the Company with prior notice of such public statement or communication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5 <U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser
is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser
could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents
or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<B><U>Non-Public Information</U>. </B>Except with respect to the material terms and conditions of the transactions contemplated by the
Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other
Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company
reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt
of such information and agreed with the Company to keep such information confidential. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company,
any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public
information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall
not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents,
employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees
or Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to
applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public
information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant
to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant
in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>&nbsp;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7 <U>Use
of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital, development and
general corporate purposes and shall not use such proceeds for the redemption of any Common Stock or Common Stock Equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8 <U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning
of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members,
partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack
of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any and all
losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements,
court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result
of or relating to any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents. If any action shall be brought against any Purchaser Party in respect of which indemnity may be
sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the
right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party
shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses
of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically
authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ
counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the
position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees
and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y)
for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld
or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s
breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other
Transaction Documents. The indemnity agreements contained herein shall be the sole and exclusive remedy available to each Purchaser Party
with respect to the matters covered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9 <U>Listing
of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on the Trading
Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares
and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market.
The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include
in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Shares
and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action
reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with
the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain
the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation,
including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation
in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10 <U>Subsequent
Equity Sales.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) From
the date hereof until sixty (60) days after the effectiveness of the Registration Statement, neither the Company nor any Subsidiary shall
(i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock
Equivalents or (ii) file any registration statement or any amendment or supplement thereto, in each case other than as contemplated pursuant
to the Registration Rights Agreement. Notwithstanding the foregoing, this Section 4.10 shall not apply in respect of any Exempt Issuances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) From
the date hereof until twelve (12) months after the effectiveness of the Registration Statement (or three (3) months after the effectiveness
of the Registration Statement with respect to any &ldquo;at the market offering&rdquo;), the Company shall be prohibited from effecting
or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents
(or a combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction
in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or
include the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or
other price that is based upon, and/or varies with, the trading prices of or quotations for the shares of Common Stock at any time after
the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being
reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent
events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects
a transaction under, any agreement, including, but not limited to, an equity line of credit, whereby the Company may issue securities
at a future determined price. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance,
which remedy shall be in addition to any right to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Notwithstanding
the foregoing, this Section 4.10 shall not apply in respect of any Exempt Issuances, except that no Variable Rate Transaction shall be
an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11 <U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of this Agreement) shall be offered or paid to any Person to
amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered to all
of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by
the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall
not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of
Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12 <U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it,
nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short
Sales, of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such
time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions
contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4,
such Purchaser will maintain the confidentiality of the existence and terms of this transaction. Notwithstanding the foregoing and notwithstanding
anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation,
warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the
transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section
4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance
with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced
pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty
not to trade in the securities of the Company to the Company or its Subsidiaries after the issuance of the initial press release as described
in Section 4.4, in each case without limiting the obligations under any agreement entered into other than in connection with the matters
set forth herein. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate
portfolio managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the
investment decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth
above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase
the Securities covered by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13 <U>Form
D; Blue Sky Filings</U>. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D and
to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably
determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers at the Closing under
applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the United States, and shall provide evidence of such actions promptly
upon request of any Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14 <U>Lock-Up
Agreements</U>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except to extend
the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If any party
to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its reasonable best efforts to seek
specific performance of the terms of such Lock-Up Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
V.<BR>
MISCELLANEOUS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1 <U>Termination</U>.
This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect whatsoever
on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been
consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>, that no such
termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2 <U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses
of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without
limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered
by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3 <U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect
to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4 <U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via facsimile
at the facsimile number or email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30
p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication
is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached
hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>)
Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt
by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the
signature pages attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5 <U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in
the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares and Pre-Funded Warrants
based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver,
by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver
disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of at least 50.1% in interest (based on the
initial Subscription Amounts hereunder) of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required.
No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall
any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed
amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to
the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser.
Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6 <U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7 <U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.
The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser
(other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns
or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities,
by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8 <U>No
Third-Party Beneficiaries</U>. The Placement Agent shall be the third-party beneficiary of the representations and warranties of the
Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended for the benefit
of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof
be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9 <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents),
and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.
If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the
obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing
party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10 <U>Survival</U>.
The representations and warranties contained herein other than Fundamental Representations shall survive the Closing and the delivery
of the Securities for a period of one year from the Closing, and shall thereupon terminate, provided that no such termination shall limit
the liability for any claim (and only such claim) asserted prior to such termination. The Fundamental Representations shall survive indefinitely.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11 <U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo; signature page were an original
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12 <U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13 <U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any
of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document
and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind
or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in
whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that, in the case of a rescission
of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded
exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and
the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Warrant (including, issuance
of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14 <U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of
and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company
of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15 <U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may
not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and
hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law
would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16 <U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a
Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or
any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or
are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17 <U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. The
Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not
because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained
in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company
and the Purchasers collectively and not between and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18 <U>No
Other Representations</U>. Each of the parties hereto hereby acknowledges that (a) there are no representations or warranties by or on
behalf of any party hereto or any of its respective Affiliates or any other Person other than those expressly set forth in this Agreement
and the other Transaction Documents, (b) no party hereto has relied or will rely in respect of this Agreement or the other Transaction
Documents upon any representation or warranty or any document or written or oral information previously made available to, furnished
to or discovered by it, other than the representations and warranties expressly set forth in this Agreement and the other Transaction
Documents, and (c) the parties&rsquo; respective rights and obligations with respect to this Agreement and the other Transaction Documents
will be solely as set forth in this Agreement and such other Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19 <U>Saturdays,
Sundays, Holidays, etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20 <U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to
share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21 <U>WAIVER
OF JURY TRIAL</U>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH
KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND
EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Abeona Therapeutics
    Inc.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address for Notice:</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With a copy to (which shall not constitute
    notice): </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: &nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK<BR>
SIGNATURE PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER
SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Purchaser: ________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Purchaser</I>: __________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ____________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: _____________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory: ______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Securities to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount: $_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares:
_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pre-Funded
Warrants: ______________ </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Common
Warrants: ______________ </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN
Number: _______________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>exhibit
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>FORM
OF WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[See
attached.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>exhibit
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>FORM
OF LOCK-UP AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[See
attached.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>exhibit
C</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>FORM
OF PRE-FUNDED WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>exhibit
D</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>FORM
OF registration rights AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[See
attached.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 38; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Abeona
Therapeutics Announces $35 Million Private Placement Financing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEW
YORK and CLEVELAND, Nov. 3, 2022 (GLOBE NEWSWIRE) &mdash; Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered
into a securities purchase agreement to sell 7,065,946 shares of its common stock, and, in lieu of shares of common stock, pre-funded
warrants exercisable for 543,933 shares of common stock, and accompanying warrants to purchase 7,609,879 shares of its common stock to
a group of new and existing institutional investors in a private placement. The offering price for each share of common stock and accompanying
warrant was $4.60, and the offering price for each pre-funded warrant and accompanying warrant was $4.59, which equals the offering price
per share of the common stock and accompanying warrant, less the $0.01 per share exercise price of each pre-funded warrant. Each accompanying
warrant will represent the right to purchase one share of the Company&rsquo;s common stock at an exercise price of $4.75 per share of
common stock. The pre-funded warrants and the accompanying warrants will be exercisable immediately, and will expire five years from
the date of issuance. Gross proceeds of the private placement are expected to be approximately $35,000,000, before deducting placement
agent fees and other expenses. The private placement is expected to close on November 7, 2022, subject to the satisfaction of customary
closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
private placement included participation from new and existing institutional investors including Adage Capital Management LP, Armistice
Capital, Deerfield Management Company, L.P., EcoR1 Capital and Nantahala Capital as well as other specialist biotech investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
intends to use the net proceeds from the proposed private placement for development, working capital and general corporate purposes.
Abeona estimates that the net proceeds from the proposed private placement plus its existing financial resources are sufficient to fund
operations into the third quarter of 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cantor
Fitzgerald &amp; Co. acted as sole placement agent on the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities being issued and sold in the private placement, including the shares of common stock underlying the warrants, have not been
registered under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), or any states&rsquo; securities laws and
may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from
the registration requirements of the Securities Act. Abeona has agreed to file a registration statement with the Securities and Exchange
Commission (the &ldquo;SEC&rdquo;) registering the resale of the shares of common stock and the shares of common stock issuable upon
exercise of the warrants issued in this private placement. Any offering of securities under a resale registration statement will only
be made by means of a prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities
of Abeona in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Abeona Therapeutics </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona&rsquo;s
lead clinical program is EB-101, an investigational autologous, engineered cell therapy for recessive dystrophic epidermolysis bullosa.
On November 3, 2022, Abeona reported that the co-primary, secondary, and exploratory endpoints in its Phase 3 VIITAL&trade; clinical
trial for EB-101 were met with a high degree of statistical significance. The Company&rsquo;s development portfolio also features AAV-based
gene therapies for ophthalmic diseases with high unmet medical need. Abeona&rsquo;s novel, next-generation AAV capsids are being evaluated
to improve tropism profiles for a variety of devastating diseases. Abeona&rsquo;s fully integrated cell and gene therapy cGMP manufacturing
facility produced EB-101 for the pivotal Phase 3 VIITAL&trade; study and is capable of clinical and potential commercial production of
EB-101 and AAV-based gene therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted
to identify forward-looking statements by such terminology as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;intend,&rdquo; and similar expressions (as well as other words or expressions referencing future events,
conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially
from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including
but not limited to, our ability to continue as a going concern; the timing and outcome of our Biologics License Application submission
to the FDA for EB-101; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome
of any future meetings with the FDA or other regulatory agencies; the ability to achieve or obtain necessary regulatory approvals; the
impact of changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other
risks disclosed in the Company&rsquo;s most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and
Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events
or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise,
except as required by the federal securities laws.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Relations and Media Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greg
Gin</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VP,
Investor Relations and Corporate Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ir@abeonatherapeutics.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !W 3L# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#9^&M+:^O-S+N")&F-SL>P_4_A6N3@5YS"!X[\=-,2'T;1CB,=5FE/?W''Y
M>M12@I.\MEN:5IN*48[O;^O(ZOPUXGM/$MO<201RP202>7)#, '4_3\_R-;E
M>=^*(YO"/BFV\3VR?Z#<D0WZ+^C?7^H]Z[^":.>WCFB</'(H964Y# \@BBI%
M*TH[/^K!2FW>$MU_29D:MXBCTG6=)TY[=Y&U&1D5PP 3&.OK]ZML'->=?$2]
M33O%'A6[='=8I97V(,LWW, #U/2M :[XQO@)].\.V\5LXS&;N<!V7L2 1CZ5
M;HWA&2Z]WYD*O:<HO6W9>1VU%<-<>)?%VD0/=ZIX=@DM(QF1[2X!9%[G!SD5
MUVF:C!JNFV]];,6AG0.I(Y^A]QTK.5.45?H:PJQF[+?S+>:,UQE_XMU2XUBY
MTOPYI OY+5@D\\D@2-&_N]LD?6D74?'JC<^B:6X_NI.0?U-5[&76R^9/MXWT
M3?R.THR*YKP_XJ.J7]QIE_8R:?J<"AW@=@P9?52.O4?G4_BCQ)!X:L([AX7N
M)II!%#!&?F=C4^SES<MM2O:PY.>^AO45Q*ZOX[G421>'K"%3R$FN<L![X-0W
M/B_Q'H:+/X@\/(EF6"M/:3AMF3CD9/\ 2J]C)Z)K[T1]8BM6FEZ,[RC(]:AM
MKB*ZM8KB!P\4JAT<=&!Y!KA;#QSJ^L1SPZ7H@N;R.9T8^9MBC4< L3U)YX'I
M4QIRE>W0N=6,+7ZGH%%<0VJ^/85\Q] TZ9!R4BN,,?S-;/A?Q/#XDM)G6WDM
MKFWD\N>"3JC?Y!].AIRIR2ONO(4:T9/EU3\U8WJ*Y;Q+XKFT?4;/2]/TYK_4
M;P,T<6\( !W)_/\ (\U3_M'Q\?F_L72U']TSDG^="I2:OHOF)UHIM:NW9':T
M5R&F^++\:[;Z-KND_8+FX!,,B2ATDQ_+\ZZ^IE!QW+A.,U=!1114EA1110 4
M444 %%%% !1110 52U+2K35K1[:\B$D9Y'JI]0>Q]ZNT4-7W$TFK,\@UG5O%
M'@_4/L/]HR2VS F"255<LOU(SD>E<S>:E>:I-Y][</-)T!;L/0#H*]#^*TL(
MT6QB8+Y[7&Y/4*%.[\.5_2O,8VXKSZ]U+EOH>#C$X3Y+MHT/%0\GPMX;3^)_
MM,I_%U _E7/Z?"US/'"K;3*X3)]SBM[QXWE'0K3_ )Y:9&[#T9RQ/]*YJUDV
M$$'!SUKZK!1MAHKR,:NE2W:WY(^D=!T"QT#3TM;., @#?(1\TA]2:U@,5YWX
M9^(]M/;Q6^L2)#,H"^=\Q#^A( X_.O0E.Y<@UY-6$XR]_<]^C.G./N;'&_$3
MQ!)I>CKI]D'?4M0)AA2/E@#P2 .<\X'N?:L3PWKM]X<T6#3X/!>K,4&9)!$0
M9'/5C\O^0!726OA)CXSG\1:A=BYDV[+:+RMHA'0<[CDXSZ<DFNJP*T]I",%!
M*_5[[_\  ,_93G-S;MT6VW_!//-2\6WVJV$UC=>!M8>&9"K QG\Q\O4=:3X;
M:W/&DOAO4HI;>ZMAO@2=2KF,\XP?3.?H?:O1<"N6\2>$VU?5K#5;*[^Q7]FW
M$OE;]Z_W2,CCK^9H52#BX-63]=Q2I5(R51.[7IL8_CLQCQGX.,N-GVE^OKNC
MQ^N*[U,%1MP1CC%<QXH\()XGO=,EGN6CBM"^]%7E]VWH<_+C;[U1;PWXHTUO
M(TCQ),+(<11S6\<AC7LNYCDXI/DG"*YK-?YC7/"I*7+=/_(ZS5@@TB\WXV>1
M)G/3&TUSGPQW_P#""6._.-TFW/IO;_Z]4YO"GB76(S;:SXGF-FW^LBAMHXRX
M]-RG^>:[+3K"WTS3H+*U39!"@1%SGBD^6,.5.[;*BI3J<[5DD>9>%--UZ\NM
M=.FZ^NG;-2E$L1M5E+-G[V3S[8]JZ0Z!XR/_ #.2_P#@NCJ35?!T\FK2ZOHF
MK3Z7>S ><(T#QRD=RI(&:J_V1XY/RGQ, /7[!#_C6LJBD[II>J_X!C&FX+E<
M6_1_\$=I?A^\M?&,%_JGB."^O5MS&(1"L3LG.#@'H#GG%1^-B@\6>$&FQY/V
MQP<]-WR;?UK3\/\ A%=)U"75;V^FU#5)EVM<2C:%7T503CI_^JKWB/P[9^)=
M.%I=&1"CB2*6,X9&'<?G6?M$JB;=U:VWJ7[)NDTE9WOO?MU^1K@9-8GC/R1X
M.U?SL;?LKXS_ 'L?+^N*PUT'QG9H(;?Q4\L:\*TEG&S8]R6R?QJ.3P3K&MLB
M^(O$5Q<VJL";:*%8@WUVDC]*480BTW+;U*G.<HN*@[OT-[P1N_X0G2-^<_9Q
MU].WZ5C_  Q11HFHL  S:E-D^O"UVD$,=O;QPQ($CC4*BCH . *Q?"V@-X=L
M+BV-QY_FW+S[MFW&[''4^E)S3C+S?^92IM2AY)_DC<(KB/!V!XT\8J. +B(_
MH]=P:P-%\/MI6NZUJ)N/,&HR(X39C9MW=\G/7VI0DE&2?7_,=2+<XM='^A@^
M(]1U>Z\:V^B:&EE!=+;>>]Y/$&9%)(PO!_ESFK0T'QMP6\7Q ^@L$-6/$7A*
M;4]5AUG3-1ET_4X8_+$B('5UYX()'J:H_P!D^.^A\2CZ_88?\:U4H\JY6EZK
M_AS%QDI/F3?H_P#AC&U2/7+;QGX7@UJXMKO%RQAN(4V,PRN0R]!CCIZUZG7"
MQ>!K^76=,U;4==FN[JUE\Q]\("D<850&PO0Y/.:[JIK2C)12Z?YEX>$HN3:W
M?7T"BBBL#I"BBB@ HHHH **** "BBB@ IKNJ(S.P50,DDX IU9VLZ:VK:>]D
M)V@CE($K*,DIW4>F>F:3VT%)M+0\\NM+O?B#XA>Z#-!I%N?*BF*_? /.T=R?
M7MQ6;K_A.'3/%.GZ;9O(\5WL_P!8067+8/0=.]>OVUK%9VT=O;QB.*-0JJO0
M 5SG]ES7WQ .H302+;6-LJ0NRX#NV22/7 )_'%82I)K7=LX*F%32OK)M7?\
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MW6;.XNK:$VJHTT$Z3*CMM#[3TS@XX]J'?4<G)7L1)KB^=''/8WMLLCA%DFC
M7<>@R"<9JWJ&HPZ?'&TH=FD<1QI&NYG;!. /H#^54O-UVXEA06-O:IYBF20W
M'F?(#R -O4CBI-<L)[VUA6&""<QRAVCF8KD8(^5ARIYZ_7UI7=A7ERNWY#K7
M5A/=)!)9W=N[YV&>, -CW!/ZUJ5S>GZ;?)J=O+]C%G#&6,G^FO-Y@(( VD8Z
MX.?:NDIQ;MJ.FY->\%%%%4:!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>abeo-20221103.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaOJGbP9z5Z8iekhvWB1bem6Py0jBxZ0SCiarA+WISYD -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:ABEO="http://abeonatherapeutics.com/20221103" elementFormDefault="qualified" targetNamespace="http://abeonatherapeutics.com/20221103">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="abeo-20221103_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="abeo-20221103_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>abeo-20221103_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>abeo-20221103_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Cover" xlink:href="abeo-20221103.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140309128451968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  03,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-15771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABEONA THERAPEUTICS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-0221517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1330
Avenue of the Americas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">33rd Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New
York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">813-4712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABEO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abeo-20221103.xsd" xlink:type="simple"/>
    <context id="From2022-11-03to2022-11-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <startDate>2022-11-03</startDate>
            <endDate>2022-11-03</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-11-03to2022-11-03">0000318306</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-11-03to2022-11-03">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-11-03to2022-11-03">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-11-03to2022-11-03">2022-11-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-11-03to2022-11-03">ABEONA THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-11-03to2022-11-03">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-11-03to2022-11-03">001-15771</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-11-03to2022-11-03">83-0221517</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-11-03to2022-11-03">1330 Avenue of the Americas</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-11-03to2022-11-03">33rd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-11-03to2022-11-03">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-11-03to2022-11-03">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-11-03to2022-11-03">10019</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-11-03to2022-11-03">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-11-03to2022-11-03">813-4712</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-11-03to2022-11-03">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-11-03to2022-11-03">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-11-03to2022-11-03">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-11-03to2022-11-03">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-11-03to2022-11-03">Common     Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-11-03to2022-11-03">ABEO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-11-03to2022-11-03">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-11-03to2022-11-03">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @
MFXIC50=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " ";BF-5#!XY"NT    K @  $0
M@ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " ";BF-5F5R<(Q &
M  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( )N*8U6/;C4/: 0  "81   8              " @0P(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " ";BF-5GZ ;\+$"
M  #B#   #0              @ &J#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( )N*8U67BKL<P    !,"   +              "  88/  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( )N*8U6JQ"(6,P$  "("   /              "
M 6\0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " ";BF-5)!Z;HJT   #X
M 0  &@              @ '/$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " ";BF-599!YDAD!  #/ P  $P              @ &T
L$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #^$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>abeo-20221103.xsd</File>
    <File>abeo-20221103_lab.xml</File>
    <File>abeo-20221103_pre.xml</File>
    <File>ex10-1.htm</File>
    <File>ex4-1.htm</File>
    <File>ex4-2.htm</File>
    <File>ex4-3.htm</File>
    <File>ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abeo-20221103_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abeo-20221103_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abeo-20221103.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ABEO",
   "nsuri": "http://abeonatherapeutics.com/20221103",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-11-03to2022-11-03",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://abeonatherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-11-03to2022-11-03",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001493152-22-030374-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-030374-xbrl.zip
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MDS4&DA-VJEU#T6%9Y\,B#0H5V!\X9M0AZ!#C.J-ED>),IN?GFV+_5^*#I96
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M5QQMF"Y!8^_K9['PC(8W*BOLR3E<HZAS8?1JS=?K+ ,1R)D,SX0$G&ZOB)&
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MU'2BB['F;.*$T,'L_X\FZ[+(FD9*E2>JI,_'(V(0D3 !3@S'"1 !CI]N?"2
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MKAC,>YY?/7KMY&%, 7,^X)1L+2&^D/T-%,L9$A(2#0^FP:GC>3&SAA+0](4
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MRE4S2YS_D^O$1MDE,^ E[7A$ X9IR-E,IS.3QIDOZ0,XH2_$C3;+YM72-'?
MKAB+I::U@K-'%3Z<%HPG<>V9T/>JCN&*F%#),=RO4!'.*XWL'#49]#7C-'$%
M8-&A\.=4_$.F% [6,I4ZIF6;/TCS8JVN$XT=>4I ]'J!QID5F?>0SE% "_$D
M3U0X%/+.TQ8/3QHZVN+(5;+A;K#V%RV2><Z>PS2;M7[-F?L-'QV/)@%3K9D2
M$U(+?BW>/6V+UL;Y@9U-L7-^K;F!P]@H.Z)L W'MUNQZO':YL+D9LAW25Z01
ML_.6%<Q.ADO?>HJ=7(N<DO_6X_:]DU]$#7802.,:O95U=KXN1 Y(-XCA[$W/
M>1E4)>83<$[1Q=J%^V -?'R$DQ[6:*&"G)Y7<%B6V @J_-;K,#R[G<G0$4^X
MZ#TNS")+V7HHR9?=VD@EJ_WXC1]-<Q!32 ')9CYO::Y;F.=J5.D^3EBHU;W
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MV-++JEEFZ!+D- J7SNF#S#;SNNU7:WS]ZJ5_GZ^NY.ID(ML,'"Q, EPDLZS
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M&$!>2NE-*='7*VXQD&;48:W7FE%75%IQ8;DE)I:J'3X^;IHU_!V^D[V57$F
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M>M>( S%L<;>UT?%,W;W3]W&/.S"HSXE[/-['/6XW[O%X'_?8;^!;8$M GLN
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M9UBA[I)X?LP/W,0/6[VQ>K#$\<6F?#?^:\QK.<M=T60^*5:M=Y(%!+DZH>E
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MPU:[1Q&:STGJ?+J'6]PNW.+I'FZQWZR?Y5'Y&WI4WN1-J]:Z=8KU78 29M'
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M]SK&M<4^.N88'U.W;(^Y5'M.AZJV7X!.UHBVJ]/.7J:^6><3" ;5_@6U"#G
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M*F":24).F^EP+!D$&26(K*SW2*U>M?Z0053=.8GRN##:G8Y(W\=DC7Q)/_N
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M5O9=U6!X6)E"37@_9GYH^K3RD!H;FQ;+P<R0&@>\M#JX(&>*PVK@R172$0>
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MX.EPK?H*##TN%%V*WX^S-(KY:Y!?*D[#"3PK*%2)(R\O^D%8PL6+H(35PR?
MB.F2;@=OC^ HT8W9I#KXPQ2>&R;!4+\2CYVW5#@&?N(LC^%?&/++UT^?!K/M
MZ7:PA3OW]RS_$NS');^^AU>;M7M[^OEX=P=/*/Y2>?D9K ?,!2=6?^]H7@9I
M5N+\<T63Z>.[8>6*<1Z/%.T9#FXVS\<7(/Z"29Y- Q;T04W.PQ)U.P<J":^
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M&</_V!H\V>L%6W_K_1,_WQKT^C 06-+7C_]4?F_PVC="TO3CMI]5EW+M*0E
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MVAELG_V,(OFRF>LJTS)%Q13%V%JT$B-YR=="C;@A_^'W[,41JUKZ3D_-DP'
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M$#&.*JXVPFHQ;(Z2[) "3I0$"<R5*9W2?$<*=E(9YR!O-2?,MG NXN;PRTQ
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MV9>B[EJFJB+HW>!,%*3+ FTN<06,\"[V4W(%+:*UA3@.Y:C ^41O2&'D%->
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MJFW_"GFZDR<JKL345V1J",(%:Z5AZ8UO"JE#W6QP7FKB:B-IS6-LCK!R3%F
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MM<B#: H)U6I 2@-@ST]5+[W#_,K+8:=;"D/ZHYYW,'1=$>,1IJ :*:V$2.8
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M<Q,7-5Q)-V ?K+:_QE_2["I1T;DJK-50-7W&$L.Z5O67GMFE@WBU+7!T4KV
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MKNK6<T4+:%_'/!JTFS5 P+R"]X@\5Q98> 5R3W-A/ /CO>E+X1G00I5ZSE.
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M]2VZ=9G1.JC,KX9/"N[14T>TIRA)QC0>$T!Z98=<.1DL3)#7)+%A*?N;.HY
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MXD=S%(Z/LB(=I1E*61U@:8'4&%<*>5A@\&P-CL34 #UZ@;F-L3"PAD-XI*Q
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M>!Q)%'-X"?R%@U28&MNEK0YR7XI1=U>LV8QB0XR#UE3: A*.YYM&X2R\4*9
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MK_?\[2+OH*Z2UTFO<G*&F_%68<A>$PIJ;,T1V\@)V&C/G D 6J#IK@A@T @
MDFP@M69:88ES=V"R-?HZ$I7-7;R$T%S13AWMMQ(-<WJ!1P%L)"43.^*K(Q9-
M&4-=*?B.FX@@.[7:6FAG;)>Q[.U^)SQ<VYZO=R[I3'=0=#FYG;NM%$_OV-5I
MYP?7XL\-)GR=76"I\-#\5<OEAQ[[OOI;6QC]=R]P1:^O_RZ],-IQXOU_X2U;
M/[G(:H!?.K46>MOF#-_$>8$.PN :_S2M6;Z#!*6'C#=ED]Q#XC-(/.S5L\XH
MGQ==9QZ6>SSSMMF5_MN[__M7O?\/>@;0,P YN<FM9P GI*ULBP-T:%:YPN(Q
M S;N0QJ#=K0DSQ3Z#:\_#TH#Y6 0XJ76WFU:I&FU(FPDT*:,V^X:_/!?].1<
M9RJB9999B6G21MNI4D>CJ<U- X$ZSJAB_ S=>ST[Z]G9;61GTUO/SD[/X_PK
M<[,6+F88TW4GHKG87^=>'D.ZWC0ZN-<ZKK5W'SG6#9N5VUS <<K1$2YW(?_U
MM"JQ\T"]G:E_$:@.Q=*;K<'785*W!K)>'"[)&Q'!RFO/Q7  G'(JN'"%> _:
M"LYA^*R4Z(N X-/DO21US/SHSO%:F[O$&V)Z +0$670B>[T:O2NQ*JR7@>,2
M+IE)^+XKUV^%[60XT[I>[L2!!>W621F1JO!RF<]4JO(HP71T97(,VH%,BPTI
MZ\/!%7+6,1"]#I"#L,XQ:MI>G2 \:6.ZBNU5\[5#*#O/-6[<CSNG#$Y+29+(
M9(FGRQ_)G^E6$5U-%-9Q(TP",71)O,2^;TVJ53N0B=1IZ&(V&K3$TD>7^->_
M5>\!(U%F.(Y4@3-&2F%W)0SL+:^[?7EQZ_M]N!.IIZ]1!Y74H&(ZX51*YB&G
M=,=O79;@E<UT]K@HI,/&%?+6[D7X<]<7-3IKC\M@:L*9"6S#KW*,: A2CX#6
MQ)SJLZ:,=J+\J$I*Z='PQ:^FX7.D6V!(\K$-*^!SOUN4&@]>HQ6&QM25\SON
M!?VM#[__V(??MQI^_[$/O_?A]]U!*GS$8(R>\/^ %?JS*N=>=CTBXRU;"EKJ
M(,Y2R15TS4R4J,8\[JQ;7Z=!;STR?H=.^UOK81'K892@*64%YY@^.WK4ZF31
M/0REK%ORF[OR4CC]Q'DW^@M&^]Z;S8O%,V+>S(4=W&+&*9F0'!Q;7>2UE>54
M39BE!>#C'IG9M)+O7<07KT6+Z=^BLT*\;W6IAMO(9=QF+LZK/(V+\WJ>]31;
MQEQ<8/)+]:3(?<.= YV>/>%PP"GV]C&GF$*\(NT+V-2 9FS26&JE_5)AZ"NT
M!;#ST\8R=8'D&BLOM[A#:PZP\$_0--_!.?$&.)YGT=87T9]9CE61ZTUP[58W
ML(@9K]9'2-(PJ!&51[G 0024MQ+TE=3-1QX.DNC2[S8QKAG;/FVX18-Z>WDV
MDINMDYQJ((R70,H'M:MH\K6' ^V0=R$)-06JF4MT:TZI[5;:G/ K#<'GTGUC
M-QVVH-EJ*\R@@#B7R?/ \M%@:Y#@7V[[!D)H%0_KPF*=ZEQXF\??@#T-1M%Z
M,-7./A%CG<.MBT5CV Z?[[4>H\=1G9+B>V% [OJB"+<//8,?KH)$[1>,7K5'
M.!6CK)&M?C'A<%!)_V1'D2LU1G(75!6!LJX!RFY%9.7P2:WZJ MH2#MFV] S
MN2G;U7?0MJ9KGW!ARV]1H6B+)G2#Z6XJG@W99<NHP"PM&[R.!6]'QWOJ%\=,
M4F2,\TM'AQG5I'('JC&WN^8V2IDWD&&Y$KHU;0"]LA3=Q2F4RD%=F"VE<Z8F
MFNJD+S"DTE(/70?\V:0-6+U-./]PP#1 DK,>9R[S2FF\ V+W-34*]!N9-3E$
M:()1ZH:T]#SIK,2WV#5'N-!K)#@K$Z KQ 4[$UTH0NNAU'HBJRZ^IA&7%J61
M=5!T(99Q697*H!VB[$@?M,+P8B=T[2IWPG7T/P;DP^JS>!9'.:=5Z]I5K<E@
M/#)QNAG*P17VRKDJC@_TU'9EA D=22=C^K"M4S=WQH[='/'-,,S^,;G(&5)O
M7&- NI[5B[E>]2[9'<"J+[J]"P4Z]HP>=N9/E]BC45W4Y2*WK4LAY_OJ-3IK
M*,G-.]UK!3NP*,+[.YZ[!-HF]JY6G! (<"N%T[A$NB"WI[Z-]@4%)\G GY#E
M$;6!WBHM')R@>-S=%(.+J-OLV9@!_G2DT469SZ-IJ>NX'3AY2H[T[7KGGGJM
M/:)TLU1OZ]?11!ZNN1IJ&T1]8]OW^5[<K/4!F[_W 9NM!FS^W@=L^H#-+O(.
M0DI[U]JSH"L!B\P+ZF>A06,X 8^D1^CA$5A8%48JR;/J[#P87<3CP#0E4:2]
MH0"*C<4$<@5&KJ8:V:..0B_RT-&?+#X&V5J@NH'I0#JJZ\A"K*GQE;JH@*4_
M.@0E$45DU.+-;#?D$*:EP[Q?:RO%G1[AT4N91,V\$=^B#P4,#XJ_&//CM,LW
M\G'$#(K8>G!\:C0" R.HF4$!TZ,;4]'Q8ZZOHQ33Y-7XV@:DOZ%@/5K<5[,Q
M!(?'24-3S&MVL+7(A#>^2L:C:VDKD#M%PG,UPVQ'LN9Q-F#1P2:D."9\&E5@
M): OFEI4K?-TKE^;3U/T*JL7.6:@MM:%YKM[(Q#\UK57H??F&CT5-K990Q.?
M#=6-^&2MO17D@IG^"NQ10B!@!BD*V<8UR7X,ZV8WA.WD.4^#;XJ@6[?9JH6%
MGI<W(L*-_0V6&WY6"P9X(8]#[?NY-LB[U\FT0GJLJ,Q_PC?%C'O]A&W;D%-@
M#K8V=>)C=E<LW)S9%+IA=E\(H(K"/_K7E#Y%9+*,B@+E+#X:Z[X(V)&AD'!?
M"C2&#H/"];19J+0UX(VF@=R<+%WX36$<D[&Y:87UP1  X+IW-BZ+%^"[>D2L
M+:*'@B.O.(R KZU[2@)->N+"*X21:#_)FDL>UF;-U](&]XI,G$Y>(<>&T(TO
M]MJ;%,2EQ8?4/>^H[I^6:K=> &;TBN<1+S?C5@:9L UO5^B96JL->FSF'K#G
M<*8^'W3/+"F53EI?@EA=FF:G<0[;@PF"\ 9VW>JH*'R]XL1O))B05@><+U$4
M8;D7-MVN+XK .7[O*'>(+K)XYHNXC!II$S '?H;.[6QBDI>1E\_RZ#)*=/,W
MECHDPD":+:4KR#IQMO:^6>!;#FNO%Q.C#7)BW"TH&N&3;D$A.=VF_YWCD0D6
MV>*^H$'M^J*HO.%-:^*([1\)]DM^ID);#85Q>V#HJ!IR(+Z&.+A&E:>'&K$8
M)RZ)?71:A#XUK\&0>I7@>E"ALQ+L+XI>#4?\N62,6U+.Q09D_SA8HD3TV >0
M8C'G\20NBZY?!OX/W9P@SIY9HN#FX*9-:& UI2-QAH(B8BK6&VMJ"\IN2&NU
MEE^183)DP$)=Z*"14\&ABY>.7O]R^#$H5@4^-D*$3O@5BM4LUZ<W]N!:[8)@
MGY?GJP*=-I06T7.$'5@4%4B<7"EVY8<ID18F*UV;8.Z&N$D:<:8F+VC-IZ-+
MZ+;@*21!1CN(_+0#0_@&BXH8Q^:BJ7H75G^J;,%MF&H8Z'PN<T'/X@O':!+_
ME.N8LA##L_&]N![KPP$_]>& K88#?NK# 7TX8!=YQ^B<X]F>2F6+Y6RFC:A>
MGB"*@)TC=9#%HV8=06ILG)8M56YP!EV09,P C::@7I54J4="$&9,H6?;G!;G
M,5,)PFZ3!NR,ZL!FH 18&\.05PAP?%!*7VGEBXK(AI'KYB%K;][H!BYZ#N\)
M:[OEH=R3)Z>! 1WJ=!G3"OQ"8;M5!" (.74*S05N<;>F=X!1PD5%56FF>V^R
M$N G"=!#6#59Z(I(]U30L204<2^$Y:XO:A2CGV4IED2''YA<@VJQ3+31X^I$
M#8R)EB"9DUGIN^W*Z!/>O3BE9+_I5*"_F\5%3J9<5!1@VQBO)&I]TIR7%%L6
MH$:Y-6GAV%8&7:DV:]NDKBVQ-4B)4-FVR3"Y>[A_^@5=-I.*6HOB.4$FIZZD
M,[BW/G67T%%=O5529+J+7;;DW YMBJW3&T%[;_4@8%EJ3W0DKEG6I U_#,'0
MC.G'G6M,=33"60PYH:T#>H/_>3AP'="!]3]_(^\S(AP@?5_)^UQ'[O?"LX[)
M5&]LM29 ;EMM#@=X)8-HDEVHCFAX+22]+AJN<7"<Q_T N9,8IF=.4@T]$#QP
MNVWI-YGVH&W:V[*JE-I9&J"*]LB^ :?"YL^(O^NZ9*2"IRU!;2_07'W'N?F5
M1%2*X>)DQ]:F/RA7B=)+D,\N%5Y,_2&(M#]!I+TO-5IT18)A8^-?KYXK2=RD
MQ!P=FEH3,CA160,"O*U\8#CH2H9VQ(7UX[I=72D'?__O!YUE":'EU^B03;QH
MGU?CB/>Q56;I#.6PM;#"U6UU1<":V=3;,M<8FF1_# ?Q//3R5Z^4$:N9Q2Q3
MA=.%D)5C! R-I4DV; "7TL&09@MU,81I9ZW7[3=BCW+E"0T1:WY:3XL[BR;F
MY[%WY>TB):"@<;"N(GI309@]AH49/N7)*&OQ",MN AIM@C':I);?=?;0\TCD
MD9_&;86[+4*X'GLUH%"<O('4N*) I(AD ]XTLC6^$HO03($#$E+[I2NQKH?*
MU1-Q3\0O1DF-B+7S =BWA#J]2,3ZHF%VS: ORJW&D><VEU-,0&3-8U$QLLM4
M-;IZD0R*YUXCWGH D,9"4Q3.;4F125M$1,HOZ=\76:GC)D;J7 @F5@;*-P9*
MV)*AR>X%KVT31JZ$*H*VUK55JK$6%TJ5Q E:<3Q:<^-JUY@%:U?Q?9:@HVZB
MN&#2@=^R?6/EH*3;EBUUTRU<"8K"*YK./,-*NPZ0P9 _*JSU13,-N3C8FBO;
M-$SW<27UI $(&F1ILK+NNS)+L'Z2(L\PP-&%P9) >C1M2^!8T+M27[N)#(.%
M[[Q4["?N(M(R?.CV*'.W!X[1<U8Z.W(O''+KHU<_]]&KK4:O?NZC5WWT:G=P
MFAZWH(\=?<9</<$>"PZQJE&)H:;D*S2FXYFR#3E!B!+'%4=YEK/[(#;>NK"6
MAU'+. =[7#-Z(-54U1/2=74&]QLGL=)E3^928./%H3I<K^QV:RP/):1MBVQ!
M4AB&.B!<^517[>C<[G:?!:564DC*&5\\RY2)KLB#N=;Q,1PT#Z!=M <8+P =
MCYW[0#0D,E,/ZUF*Y26V@)C5XX#*=6HJ#$]0>LQ;-&Y7.:,"FXZ?U5S-YBUT
M=EI+^2W*/ZG2-DC6 V@M$H4W.523F *JU&VYY!_;JACR/WC4YCJKV!->>&43
M+T'B!2>?5M@IU?.!$I@.S]DG0*=8QSFMX:#MS,UI@2XZ 2K4V-YS<SP:YL-Y
M>]V#8J;H)<(67D6%)H.N8MVQE/ L0=FEJ1ORV4!Q'IV97WO!6EQ"UZA8 H;C
M+K"1;7I&.'<J4<MS3,+T M!Z'*E*N?;.A52T44-: $)@,QPK$PHP'2B<$_M1
MA@*=6055)8C*:)[D6I!XW,+W=,\^8D8?Q!X!\YWA+)HT8T^5244[YXIJL?#L
M>PJ@B]^K$5WT62>![>MZIS;8#?;X+^%-II9$BHG @,$] 4: WE&7FU=YWL##
MV=:$VZAM.'#)C5#>HH20.!H;3E;7'.B.')+X)8R4K?!L1.P@<2;JC NVA+%1
MJ^-*;@'G$= K38@T32L,G$4P+^N/;I5T:_<&.9/DRZVQ[[*TWFQ-:<]W9'GE
M<&"=DGC(ZU&;&V>,'^?9)Q:3!6POML&<&GY=Z*4;8&>3_>>E6CC=#K@,B;X[
MM><=O-9)NV)!TM;3UIE2G6E6E$9*:6B\.Z$RW2'M[PEK?\?P_D5J9$R/.7NK
MC7Q"(6V>6DWXL/+><&B']1:W''3"W*K48>^UWKXR$N>,8*I(<![EBX1J@+SJ
M"\EB)E8=2EO:#/^X4.@NA#]@@]Z4_N1S\I'V%OFBE96Y8%ZE4Z[N16@U8)87
M44)J;48^<>#BNFP!9T<Z.GNK2JJ\:*PY((^%]C318WX9,WTT-A4BS,<6H4T!
ME^$NSS/M92PXX=KU2XV,:PX48!7I8E2=++3_I ,J"MO/R#,'#_4S;JB4ZO O
M%49E24&.<ZV"4YGW^B-P$WZ\ SDS52O;.!>;+W2C1T./R1&01:4+7UBF@>U4
M)0F%;%KR"!TS 2R!T&*B16<1PB@$.E$*Q6^2%:2I3I,H7N#>LK<T-/HFP=ZQ
MX-NH\3@!I:@LT>1=%6+%D20=^UK("/TU?+SHZK38FV]I4B[ )H5UM=8"?\GC
M@NBN*MDR1^/6PKLAE*E3W\JJHCJ#[;E*Q:M%<EL+EE3+L.'CI++N!1L8[E=2
MNK<)L]@^N<REHVV^<EY%!8B-Q?O0=DA3'@" +#TST ;-)6\MA:J6!D7UD@=C
M9B(7<99$NI1=S\I^V*C6;\T^J#,-KWS<546)].5+3.T0(M&9'3QAP2OOT()K
M_I]ZH$2G2/A6@4[@VB=:/PA<&G=(W+B(_DMO@$?OSQ";5FNL^$6('YQGEXB^
MP7\WH9VX)C.)-\.D-+=] L(5/386M1DYQ$H3"UXV.* &47$WOVHI6KX^%S-?
M\6Y0N(/2)9!B::_H-VZTPJM$TQZ'6FQNLJ(30D)0,-%YX#9E 98!HH"J]"0&
M;5+V+("NR4#7<1T?.C$A"Y_\9DX3F'KW-XVZ,APP^)]@_Y5Y/*FND/1Q288/
MHJI(K,C.G%I 733ZV;NBM;%,\D[1O1H1<B3^AL@.Q%WF='22WV/"O1F&D8T/
M V$M[&- 7!E&A]!NE ;Z"HE[C$HJ-)8<WJ/=F4A!<4J)>KSQ'!0U>;JN>"39
M _H$IPG)AYC:FY=:3Z/'D0AQ9I3\/EMG=.*:D5R% ^GZ.(F>BC^DR>9SC_^M
M8?C\UI;UT]D2W.BTI$=USNY%7/@;)?I+VH4":PQS1U)KU0M/<,9O]"#!Z6PT
M["SE^>(\G%'1P'70I/%1*7K+,3^.Z-XP6XT+&GML :&!W%9\SJ6RA^3V^8PH
MD(N4X%Q60HH07YB^GH*8ZQ=9A)*5[21VSMP9^ *A#VO"#_NXYE;CFOL/^\!F
M']C<1>Y!X//M_A+Q2[*OQ.VI(+Z2 E5(LFUU=Y8_LS@MT0);XQ/QXQ.H"ELK
MW+7-V^SML-.[X&F 7^I8P+%,842':R$T,M=Q'C1FC6$HXR30UGK3#"],&5^7
M&<ZHA1OM<)"[;\7^]LQ;7_:N4\V?;K1U06N[NK'K1*#7F[OA=8U:-@&W8M4&
M?\6HM1KU7[!JT9KJ,CK6JIYQ83?<((RY9HK76,4W%*A-BV,<U:IDW9ODVQ$6
M<JT-EMQ%56\IV=* 1]>TL=H::[N/FF",W'?IMH*3Z6BWHK'.#"SF#=IGP\%5
M#;2U,'5_U69CC,":T=9R0%>_A]B!YNJN&*W/WX K)FCUQ'3%!YW8-]WS6L(O
M7.XS D;DK5A(>:E @,]0=\KUQZ86-&,T==/:HG;2E2Z6[8 L\1"Z7"!$][D:
M/=3L,;D_O@"W#J9[8?#L^J(([I_<>>FLFA)YU54R![>4=;+C!G*G31.C<D^^
M2>0D4;[77E0HQ#(H$YW(1</AW;"9VR.@?>MK-#/"TN(H+U>^9YWHL/&,3,I4
M>Z46$KKAVS%SH,97!:]AA(\V)[$B/:H^"T?6656M^1.9%*7'D_.%BG51/RBP
M&)3ONYIC>$$$/1:]N:!?2C0\K0_I%!PG78I+SB)4$E=:[C6W1T]R&9EW16U9
MA2CFNY,M9+*!F6NS6[OK8@$2:,X$IGB&A0$,V>! ;Y/:DG.[&796M>QHBV,;
MJ,^)_G@YA_4HJJ1:4$ -$]9;%86X-!3.H')H?,P4!V@UH@@<1"XGLE@J^K$+
M=*BAQ?7/3!H\%0E:E"P0I8I39D"/*KF\'<7]V-%99$>U/Y.H2:N.8A8)U@##
MC/P)Q#-5731Y+_CT!L?4?N^8VJYC:K]W3/6.J5WD'H=@/'7I$DVQS;(8]'E"
M<E)&&HM%HVT=K2<)V!%F=\33>(F_$(V[(4<GF)O0GOQH'3L\F-&^-)2NS:GL
M4(T0?QSGH# (C-XQ=L.TRP?0R]#$XQQL/_ZYC&2-C4F&9*IM5H)0E''PB;6T
M5E7(MC]J[J6<P!74H(Z]:#\J1DI^Q$M &*D9GQIY!YR<(F="M7[-,;;[BV;V
MAV-M9H'@T"!AW6I9<]M8K]0+U9 [7;3J;(0T[&,%PG$R(?!N$K/23^G'[ F,
M,55&XI#4AD(/26 QL)$&CTP.Y3J+P%W2*&-1P0G@'3OA(<ZTO,DE18JI@IJF
M$NH%N.9F-N](UVZO)5[4VKJT>#Z8VHTV>^+D&+5>[30+%AF#R'"W\<82UMSW
M^ISAQN"DQYQTN'8U$W93.&G+A2K+Q#I>6TB>@:/@Q'2U FKB>"B@_FK\5@&5
M&P[D[_Z05>H0*K[E'(0>XT(ET4K-]@)0*+KF;:LDV"6"X>/:Z/5-H8X\<L \
M^XZE:H!U9[64(B(]%.9"Q.T6#<(?T[6G E@*/]#6.<,(+Z#\1'C&0(-0HP8$
MQU['O]D3C]EOVK&$KE5.@0M,G;";7P"7OK1]Y)Q5W0OM?]<7)2C*E)E 91Y=
M,,H>YY>J'BD+P& #AR:6V13KNSK+U[I$R@2=!?',S*+Q7"T*I,-A<!OK!?#Z
MEHJUKWED[<4N-V[X%;K5-*-,Y"I>4,%2%R^W;7BR7#O?V_49-QBF=0D#B(.O
M87;0I6,4P5=Q&U"^9-UO(+DW<'HM;C?CY;LR\,ZNW9T[R1"HR1V[;4WDR#AG
MVW(JV:WJ9E2BD'TRFHP%4</-FP*)U&HS8#4>AIQCJ3'&,!?)K^;3)NRNE0D=
M)Z:\,@JG=VHC4[THD\0EL0_D/M21+EKI!*OZA3/"78<**=S&EYNQ]2A6!;I"
M5(HR.T\D 4\"MF25(/A6IVY(G*'5DFBM+!0^$;J!62>H*A*;$;\<\%K>,;>F
MP(6\3-0%NC0Q1%S29J#"$V.#-!J,%3Z]($2BE!5Y&[9Q28;Q^VS+[7@1XNE@
MW)OK ,XQ3A":TG"*ZTTEK7<X^)=$1&O ;U^8Z.XE15XIIAYBN!)1<! .,OJD
MZ'>4MC=9A29FSR%@+ZR-T<B8%A]V;B'\O$TD&C\[68&ZG, >#77KAIE]2K-+
M8,[4'X6PJ.J3(!_U$JFYHE@%P0%R&B5>BERBCE8TA>U1?*8-_TX-!\ZE$MW5
M0Z(3M5B(TJ$+#=]J"NYK[<IM?47A-QAOZ"Z83;ZN L.4,>JBQF8YJ.8(R^:%
MM'7NCDK?DB2Z9)\'-[>W.**Q<[*F45US(NW<MUFZZ:2W4\JLRW[=:;0@K%*[
M&%0 [X6DWN"X/^@=]]MUW!_TCOO><;^+W.,434+MHY6,(7):FQ@NLW1Q/.&L
MV,(S&E0\MZIG'5>V5I T&[,WU%>+@,T'H']%H!,G26:;K5(':*VZV;0OYR&:
MHL&,)>15!)L/7*SY+E4O:('%B1<@E5'%35985Z&F+.[0D7B61\OSKD0E;_TV
MI.[5,G4GJ*W-8QH.UB<RC5)EDA",/"7MI);9U"'5R?OEY5SZ9Z85,>RWK"=
M@+@"K^<.@0$/@XC'\M]-QL2PQT0C-!NE^BHZ;+Z^M''LI7,!R6[*XG)WORT[
MJ^,\[X7FL.N+(H9F,Y,X^.,<9Z159R<GMZ%<HA\XML T.A79^HU-FD[#H$&:
M0FA(U($[?7Y7 +G=M7V_0U B/S*4R&]Q,57 >U.5544/)'*KJ4\#B7Q$NSK6
M>'_'+ 587),P1AT;&'R]Z#SWVEME;G]>#XYB8R%XZ(&(Z.1U4T#3VJ7;YS.<
M.>[ZG-5G[&Z 2+H8IL"@*4BM/$H%]R&)+HG+=4S'>HQ 2&:Z4Y;!>S N"7=$
M@=F?MI7"RP3:1I.Z(Q_.+Z#VC>ZF$ <6]]TB _T%*S&T/F&U3;'^87- A^!
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M/'>H@0M5N1C_#/.*B<]:WG&DT^P.IV(]B%JK8SI"8%Y1K/"!YIW41 W,IDI
ME59956 EFO4'"<S=(OJ$$@5MY@M]G4N\N<3IM"Z%]D*6"E:>#L.XBU,XJ2D%
MM6%'LAFB_KG<Y:-9<_ ;J/1+>"9W7X[N8)VR6%]E[:)WJF2&#U63/V7NSA2!
M>5_$8O',^0*Z6\X@6N==YT1>/3HL5X/S5N5XWTB2,F ,_(D-2H/:P"B(CA\.
M.9*SO>MB=YY 8?K8"_Y0O'0X2MS,9:S?[(LLRT%DW]NU"9P=L3W7I%OH<TE%
M[]'NNP@'7+4-!P\IM!AML"XBB>P=/6R/M6B1A$=F<X>#R:JA/;#,_?M!I\R]
MRUZ?#4&KG_N@U7:#5C_W0:L^:'4K,8F?OWQQ L0!A#$<G/QZ^/%(6COM)%;T
MUP.Z_IJN+5^D*U8"G'B*LG"\YU&NC%N) CD8_EKFZB(FK0VT_:)BL=OUNU#4
M%_PA/BUBGFWR]A]4RXS,DGP:%T8&7U)B4 FVU1M4-43GHKB-M='9G: ][S0<
M\$71.7 &-!#]G7=A..!M()^$C(# SL8O_T'@DC^ ^#%JX(EYRRO>RQ/SDC_D
M)>+##Z()F'2D".'^:5/-Q ;TBVJG$J/516I$)DF9W>>"L3X\/O>%J >+YMW
MK=Y#?1Z3BK2RG%VF\)[S>$GS\*;E:]=:#[4;U3DI4M/8K\X! S@@6#8<5ZY$
M<<4!27.J6+$7(V(9(>0VF.EP!N1AN,-JTVXNA9A(2?=XHI+L$FP*R2[H8!Q
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MFQ?39YO<LJ6\X@+RX2!19\!4IUE:B+6%E1E(#D1QG..91@M.(G,231Q9VD8
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MF?&UWV=\W<J,KUOL.+H=W&,T;=>AWD5EA7T>-/;T!X:V'0EDJHI2C!NE\I0
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M^1@;=GA7MXE*;4$_T*Z;*H1#'($LVB5,-*#L1=&'9X.\MA5 FR'WX1S%!%
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M+3(P,C(Q,3 S+GAS9%!+ 0(4 Q0    ( )N*8U4:! MF_0H  ("&   5
M          "  84#  !A8F5O+3(P,C(Q,3 S7VQA8BYX;6Q02P$"% ,4
M" ";BF-5UH?^7EP'  #I5P  %0              @ &U#@  86)E;RTR,#(R
M,3$P,U]P<F4N>&UL4$L! A0#%     @ FXIC59!Y7C]VC@  B9@#  H
M         ( !1!8  &5X,3 M,2YH=&U02P$"% ,4    " ";BF-5D;5+@R$_
M  "SK0$ "0              @ 'BI   97@T+3$N:'1M4$L! A0#%     @
MFXIC5;]@#+[0-@  (6L!  D              ( !*N0  &5X-"TR+FAT;5!+
M 0(4 Q0    ( )N*8U6)'>Z(:%@   B] @ )              "  2$; 0!E
M>#0M,RYH=&U02P$"% ,4    " ";BF-5 -A>H0H-   N.@  "@
M    @ &P<P$ 97@Y.2TQ+FAT;5!+ 0(4 Q0    ( )N*8U5PRI'_@A@  -C
M   +              "  >*  0!F;W)M."UK+FAT;5!+!08     "0 ) !,"
(  "-F0$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
